Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Jan. 31, 2015	Mar. 18, 2015	Jul. 31, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	STREAMLINE HEALTH SOLUTIONS INC.
Entity Central Index Key	0001008586
Document Type	10-K
Document Period End Date	Jan. 31, 2015
Amendment Flag	false
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--01-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 90,947,975
Entity Common Stock, Shares Outstanding		18,603,289

Consolidated Balance Sheets (USD $)	Jan. 31, 2015	Jan. 31, 2014
Current assets:
Cash and cash equivalents	$ 6,522,600	$ 17,924,886
Accounts receivable, net of allowance for doubtful accounts of $665,962 and $267,264, respectively	6,935,270	7,999,571
Contract receivables	191,465	1,181,606
Prepaid hardware and third party software for future delivery	55,173	25,640
Prepaid client maintenance contracts	935,858	909,464
Other prepaid assets	1,437,680	1,407,515
Deferred income taxes	220,004	95,498
Other current assets	207,673	144,049
Total current assets	16,505,723	29,688,229
Property and equipment:
Computer equipment	2,381,923	3,769,564
Computer software	964,857	2,239,654
Office furniture, fixtures and equipment	683,443	889,080
Leasehold improvements	724,015	697,570
Property and equipment, gross	4,754,238	7,595,868
Accumulated depreciation and amortization	(1,617,423)	(6,676,824)
Property and equipment, net	3,136,815	919,044
Contract receivables, less current portion	43,553	78,395
Capitalized software development costs, net of accumulated amortization of $11,846,468 and $7,949,352, respectively	9,197,118	10,238,357
Intangible assets, net	9,500,317	12,175,634
Deferred financing costs, net of accumulated amortization of $13,677 and $98,102, respectively	387,199	44,898
Goodwill	16,184,667	11,933,683
Other non-current assets	823,723	500,634
Total non-current assets	39,273,392	35,890,645
Total assets	55,779,115	65,578,874
Current liabilities:
Accounts payable	2,298,851	1,796,418
Accrued compensation	865,865	1,782,599
Accrued other expenses	563,838	554,877
Current portion of long-term debt	500,000	1,214,280
Deferred revenues	9,289,076	9,658,232
Current portion of note payable	0	300,000
Current portion of capital lease obligation	781,961	105,573
Total current liabilities	14,299,591	15,411,979
Non-current liabilities:
Term loans	9,500,000	6,971,767
Warrants liability	1,834,380	4,117,725
Royalty liability	2,385,826	2,264,000
Swap contract	0	111,086
Note payable	0	600,000
Lease incentive liability, less current portion	342,129	74,434
Capital lease obligation	582,911	121,089
Deferred revenues, less current portion	964,933	0
Deferred income tax liabilities	229,579	816,079
Total non-current liabilities	15,839,758	15,076,180
Total liabilities	30,139,349	30,488,159
Series A 0% Convertible Redeemable Preferred Stock, $.01 par value per share, $8,849,985 redemption value, 4,000,000 shares authorized, 2,949,995 issued and outstanding, net of unamortized preferred stock discount of $2,212,007 and $3,250,317, respectively	6,637,978	5,599,668
Stockholders' equity:
Common stock, $.01 par value per share, 45,000,000 shares authorized; 18,553,389 and 18,175,787 shares issued and outstanding, respectively	185,534	181,758
Additional paid in capital	78,390,424	76,983,088
Accumulated deficit	(59,574,170)	(47,562,713)
Accumulated other comprehensive loss	0	(111,086)
Total stockholders’ equity	19,001,788	29,491,047
Total liability and stockholders' equity	$ 55,779,115	$ 65,578,874

Consolidated Balance Sheets (Parenthetical) (USD $)	12 Months Ended
Consolidated Balance Sheets (Parenthetical) (USD $)	Jan. 31, 2015	Jan. 31, 2014
Allowance for doubtful accounts	$ 665,962	$ 267,264
Accumulated amortization of capitalized software development costs	11,846,468	7,949,352
Deferred financing costs, accumulated amortization	13,677	98,102
Common stock, par value (USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized	45,000,000	25,000,000
Common stock, shares issued	18,553,389	18,175,787
Common stock, shares outstanding	18,553,389	18,175,787
Series A Preferred Stock
Preferred stock dividend rate	0.00%	0.00%
Convertible redeemable preferred stock, par value (USD per share)	$ 0.01	$ 0.01
Convertible redeemable preferred stock, redemption value	8,849,985	8,849,985
Convertible redeemable preferred stock, shares authorized	4,000,000	4,000,000
Convertible redeemable preferred stock, shares issued	2,949,995	2,949,995
Convertible redeemable preferred stock, shares outstanding	2,949,995	2,949,995
Unamortized preferred stock discount	$ 2,212,007	$ 3,250,317

Consolidated Statements of Operations (USD $)	12 Months Ended
Consolidated Statements of Operations (USD $)	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Revenues:
Systems sales	$ 1,214,879	$ 3,239,569	$ 1,463,225
Professional services	2,580,167	3,641,731	3,792,569
Maintenance and support	16,157,371	13,986,566	11,211,197
Software as a service	7,672,990	7,626,837	7,299,812
Total revenues	27,625,407	28,494,703	23,766,803
Operating expenses:
Cost of systems sales	3,536,495	3,142,525	2,747,230
Cost of services	3,458,984	4,052,113	3,087,997
Cost of maintenance and support	3,087,842	3,460,500	3,245,569
Cost of software as a service	2,920,403	2,523,184	2,512,156
Selling, general and administrative	16,225,574	14,546,335	10,060,469
Research and development	9,756,206	7,088,077	2,948,313
Impairment of intangible assets	1,952,000	0	0
Total operating expenses	40,937,504	34,812,734	24,601,734
Operating loss	(13,312,097)	(6,318,031)	(834,931)
Other income (expense):
Interest expense	(748,969)	(1,765,813)	(1,957,010)
Loss on conversion of convertible notes	0	0	(5,970,002)
Loss on early extinguishment of debt	(429,849)	(160,713)	0
Miscellaneous income (expenses)	1,592,449	(3,573,091)	494,677
Loss before income taxes	(12,898,466)	(11,817,648)	(8,267,266)
Income tax benefit	887,009	100,458	2,888,537
Net loss	(12,011,457)	(11,717,190)	(5,378,729)
Less: deemed dividends on Series A Preferred Shares	(1,038,310)	(1,180,904)	(176,048)
Net loss attributable to common shareholders	$ (13,049,767)	$ (12,898,094)	$ (5,554,777)
Basic net loss per common share (in dollars per share)	$ (0.71)	$ (0.94)	$ (0.48)
Number of shares used in basic per common share computation (shares)	18,261,800	13,747,700	11,634,540
Diluted net loss per common share (in dollars per share)	$ (0.71)	$ (0.94)	$ (0.48)
Number of shares used in diluted per common share computation (shares)	18,261,800	13,747,700	11,634,540

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
Consolidated Statements of Comprehensive Loss (USD $)	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Statement of Comprehensive Income [Abstract]
Net loss	$ (12,011,457)	$ (11,717,190)	$ (5,378,729)
Other comprehensive gain (loss), net of tax:
Fair value of interest rate swap liability	(3,436)	(111,086)	0
Reclassification adjustment for loss on settlement of interest rate swap liability realized in net loss	114,522	0	0
Other comprehensive income (loss)	111,086	(111,086)	0
Comprehensive loss	$ (11,900,371)	$ (11,828,276)	$ (5,378,729)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

- Definition

Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).

+ References+ Details

Consolidated Statements of Changes in Stockholders' Equity (USD $)	Total	Common stock	Additional paid in capital	Accumulated deficit	Accumulated other comprehensive loss
Stockholders' equity, beginning balance at Jan. 31, 2012	$ 7,998,524	$ 104,338	$ 38,360,980	$ (30,466,794)	$ 0
Shares, beginning balance at Jan. 31, 2012		10,433,716
Statement of Changes in stockholders' equity
Stock issued to Employee Stock Purchase Plan and exercise of stock options, Shares		149,764
Stock issued to Employee Stock Purchase Plan and exercise of stock options	282,628	1,497	281,131
Restricted stock issued, shares		137,325
Restricted stock issued	0	1,373	(1,373)
Conversion of note payable, Interpoint, shares		1,529,729
Conversion of note payable, Interpoint	3,116,182	15,297	3,100,885
Conversion of Series A Preferred Stock	2,685,973		2,685,973
Stock consideration for acquisition, shares		393,086
Stock consideration for acquisition	1,501,609	3,931	1,497,678
Issuance of common stock warrants	2,441,852		2,441,852
Issuance costs	(263,072)		(263,072)
Reclassification of warrants from equity to warrants liability	(4,138,783)		(4,138,783)
Interest rate swap	0
Share-based compensation expense	956,144		956,144
Deemed dividends on Series A Preferred Stock	(176,048)		(176,048)
Issuance of Series A Preferred Stock at fair value	9,182,652		9,182,652
Reclassification of preferred stock to temporary equity at redemption value	(4,749,630)		(4,749,630)
Net loss	(5,378,729)			(5,378,729)
Stockholders' equity, ending balance at Jan. 31, 2013	13,459,302	126,436	49,178,389	(35,845,523)	0
Shares, ending balance at Jan. 31, 2013		12,643,620
Statement of Changes in stockholders' equity
Stock issued to Employee Stock Purchase Plan and exercise of stock options, Shares		602,469
Stock issued to Employee Stock Purchase Plan and exercise of stock options	1,356,060	6,025	1,350,035
Restricted stock issued, shares		29,698.00
Restricted stock issued		297	(297)
Conversion of Series A Preferred Stock, shares		1,050,000.00
Conversion of Series A Preferred Stock	3,150,000	10,500	3,139,500
Stock consideration for acquisition, shares		400,000.00
Stock consideration for acquisition	2,700,000	4,000	2,696,000
Issuance of common stock		3,450,000.00
Issuance of common stock warrants	22,425,000	34,500	22,390,500
Issuance costs	(1,838,381)		(1,838,381)
Reclassification of warrants from equity to warrants liability	0
Warrant valuation adjustment	(412,352)		(412,352)
Interest rate swap	(111,086)		0		(111,086)
Share-based compensation expense	1,660,598		1,660,598
Deemed dividends on Series A Preferred Stock	(1,180,904)		(1,180,904)
Net loss	(11,717,190)	0	0	(11,717,190)
Stockholders' equity, ending balance at Jan. 31, 2014	29,491,047	181,758	76,983,088	(47,562,713)	(111,086)
Shares, ending balance at Jan. 31, 2014		18,175,787
Statement of Changes in stockholders' equity
Stock issued to Employee Stock Purchase Plan and exercise of stock options, Shares		257,296
Stock issued to Employee Stock Purchase Plan and exercise of stock options	515,124	2,573	512,551
Restricted stock issued, shares		120,306
Restricted stock issued		1,203	(1,203)
Reclassification of warrants from equity to warrants liability	0
Interest rate swap	111,086				111,086
Share-based compensation expense	1,934,298		1,934,298
Deemed dividends on Series A Preferred Stock	(1,038,310)		(1,038,310)
Net loss	(12,011,457)			(12,011,457)
Stockholders' equity, ending balance at Jan. 31, 2015	$ 19,001,788	$ 185,534	$ 78,390,424	$ (59,574,170)	$ 0
Shares, ending balance at Jan. 31, 2015		18,553,389

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
Consolidated Statements of Cash Flows (USD $)	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Operating activities:
Net loss	$ (12,011,457)	$ (11,717,190)	$ (5,378,729)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities, net of effect of acquisitions:
Depreciation	1,005,283	718,097	726,406
Amortization of capitalized software development costs	3,677,991	3,192,157	2,659,365
Amortization of intangible assets	1,396,317	1,341,734	583,535
Amortization of other deferred costs	189,107	385,461	241,478
Amortization of debt discount	47,552	4,327	111,583
Valuation adjustment for warrants liability	(2,283,345)	(140,928)	(489,434)
Deferred tax expense (benefit)	(720,582)	20,885	(2,935,522)
Valuation adjustment for contingent earn-out	0	3,580,441	86,839
Other valuation adjustments	128,855	(95,368)	0
Net loss from conversion of convertible notes	0	0	5,970,002
Loss on impairment of intangible assets	1,952,000	0	0
Loss from early extinguishment of debt	315,327	160,713	0
Loss on disposal of fixed assets	180,793	0	0
Loss on exit of operating lease	234,823	0	0
Share-based compensation expense	1,934,298	1,660,598	956,144
Provision for accounts receivable	440,771	330,907	67,464
Changes in assets and liabilities, net of assets acquired:
Accounts and contract receivables	2,157,977	827,435	(2,923,242)
Other assets	(637,348)	(439,477)	(1,129,255)
Accounts payable	600,263	275,360	526,149
Accrued expenses	(1,422,571)	259,771	992,285
Deferred revenues	(197,698)	(152,210)	(180,200)
Net cash (used in) provided by operating activities	(3,011,644)	212,713	(115,132)
Investing activities:
Purchases of property and equipment	(2,125,240)	(152,283)	(576,736)
Capitalization of software development costs	(619,752)	(614,028)	(1,999,676)
Payment for acquisition, net of cash acquired	(6,058,225)	(3,000,000)	(12,161,614)
Net cash used in investing activities	(8,803,217)	(3,766,311)	(14,738,026)
Financing activities:
Proceeds from term loan	10,000,000	4,958,333	9,880,000
Principal repayments on term loans	(8,297,620)	(10,348,214)	(312,500)
Principal repayments on note payable	(900,000)	0	0
Principal payments on capital lease obligation	(368,386)	(34,391)	0
Payment of deferred financing costs	(573,002)	(115,900)	(1,271,862)
Proceeds from private placement	0	0	12,000,000
Proceeds from exercise of stock options and stock purchase plan	551,583	1,356,060	282,628
Settlement of earn-out consideration	0	(1,300,000)	0
Proceeds from the sale of common stock	0	20,586,619	0
Payment of debt success fee	0	(1,124,279)	(467,906)
Net cash provided by financing activities	412,575	13,978,228	20,110,360
(Decrease) increase in cash and cash equivalents	(11,402,286)	10,424,630	5,257,202
Cash and cash equivalents at beginning of year	17,924,886	7,500,256	2,243,054
Cash and cash equivalents at end of year	6,522,600	17,924,886	7,500,256
Supplemental cash flow disclosures:
Interest paid	518,919	2,422,997	1,626,750
Income taxes (received) paid	(80,467)	375,688	84,990
Conversion of $3,000,000 note payable to common shares	0	0	3,116,182
Conversion of 1,050,000 shares of Series A Preferred Stock to common shares	0	3,150,000	0
Issuance of 393,086 shares of common stock, as part of Meta purchase price	0	0	1,501,609
Issuance of 400,000 shares of common stock, as part of settlement of earn-out consideration	0	2,700,000	0
Issuance of $900,000 note payable as part of settlement of earn-out consideration	0	900,000	0
Deemed dividends on Series A Preferred Stock	1,038,310	1,180,904	176,048
Issuance of warrants to placement agents	0	0	753,737
Reclassification of warrants from equity to warrants liability	0	0	4,138,783
Conversion of notes issued in conjunction with the private placement to Series A Preferred Stock, at fair value	0	0	9,182,652
Interest rate swap contract	$ 0	$ 111,086	$ 0

Consolidated Statements of Cash Flows (Parenthetical) (USD $)	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Statement of Cash Flows [Abstract]
Face amount of debt converted		$ 3,000,000
Series A Preferred shares converted	1,050,000
Shares issued in conjunction with acquisition	400,000	393,086
Face amount of debt issued for earnout consideration	$ 900,000

Organization and Description of Business	12 Months Ended
Organization and Description of Business	Jan. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	ORGANIZATION AND DESCRIPTION OF BUSINESS Streamline Health Solutions, Inc. and subsidiaries (the “Company”) operates in one segment as a provider of healthcare information technology through the licensing of its Electronic Health Information Management, Patient Financial Services, Coding and Clinical Documentation Improvement and other Workflow software applications and the use of such applications by software as a service. The Company also provides implementation and consulting services to complement its software solutions. The Company’s software and services enable hospitals and integrated healthcare delivery systems in the United States and Canada to capture, store, manage, route, retrieve, and process vast amounts of patient clinical, financial and other healthcare provider information. Fiscal Year All references to a fiscal year refer to the fiscal year commencing February 1 in that calendar year and ending on January 31 of the following year.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References+ Details

Significant Accounting Policies

12 Months Ended

Jan. 31, 2015

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements include the accounts of Streamline Health Solutions, Inc. and its wholly-owned subsidiaries, Streamline Health, Inc and Unibased Systems Architecture, Inc. All significant intercompany transactions are eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Cash and Cash Equivalents

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash demand deposits. Cash deposits are placed in Federal Deposit Insurance Corporation (“FDIC”) insured financial institutions. Cash deposits may exceed FDIC insured levels from time to time. For purposes of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

Receivables

Accounts and contract receivables are comprised of amounts owed to the Company for licensed software, professional services, including maintenance services and software as a service and are presented net of the allowance for doubtful accounts. The timing of revenue recognition may not coincide with the billing terms of the client contract, resulting in unbilled receivables or deferred revenues; therefore certain contract receivables represent revenues recognized prior to client billings. Individual contract terms with clients or resellers determine when receivables are due. For billings where the criteria for revenue recognition have not been met, deferred revenue is recorded until all revenue recognition criteria have been met.

Allowance for Doubtful Accounts

In determining the allowance for doubtful accounts, aged receivables are analyzed monthly by management. Each identified receivable is reviewed based upon the most recent information available, including client comments, if any, and the status of any open or unresolved issues with the client preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables. During these monthly reviews, the Company determines the required allowances for doubtful accounts for estimated losses resulting from the unwillingness or inability of its clients or resellers to make required payments. The allowance for doubtful accounts was $666,000 and $267,000 at January 31, 2015 and 2014, respectively. The Company believes that its reserve is adequate, however results may differ in future periods.

Concessions Accrual

In determining the concession accrual, the Company evaluates historical concessions granted relative to revenue. The concession accrual was $58,000 at both January 31, 2015 and 2014.

Bad debt expense for fiscal years 2014, 2013 and 2012 are as follows:



	2014		2013		2012
Bad debt expense	$	440,771	$	330,907	$	67,464

Property and Equipment

Property and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related assets. Estimated useful lives are as follows:



Computer equipment and software	3-4 years
Office equipment	5 years
Office furniture and fixtures	7 years
Leasehold improvements	Term of lease

Depreciation expense for property and equipment in fiscal 2014, 2013 and 2012 was $1,005,000, $718,000 and $726,000, respectively.

Normal repair and maintenance is expensed as incurred. Replacements are capitalized and the property and equipment accounts are relieved of the items being replaced or disposed of, if no longer of value. The related cost and accumulated depreciation of the disposed assets are eliminated and any gain or loss on disposition is included in the results of operations in the year of disposal.

Leases

On April 10, 2012, the Company entered into an amended lease obligation to lease 8,582 square feet of office space at 1230 Peachtree St. NE in Atlanta, Georgia. The lease commenced upon taking possession of the space and ends 72 months thereafter. The Company took possession of the space during the third quarter of fiscal 2012. Upon relocation, the Company completely vacated the previously leased premises within the same building. The provisions of the lease provide for rent abatement for the first four months of the lease term. Upon taking possession of the premises, the rent abatement was aggregated with the total expected rental payments, and is being amortized on a straight-line basis over the term of the lease.

On December 13, 2013, the Company entered into an amended lease obligation to lease 24,335 square feet of office space in the same building as the office space in Atlanta, Georgia. The lease commences upon taking possession of the space and ends 102 months thereafter. The Company took possession of the new space during the second quarter of fiscal 2014. Upon relocation, the Company completely vacated the previously leased premises within the building. The provisions of the lease provide for rent abatement for the first eight months of the lease term. Upon taking possession of the premises, the rent abatement and the unamortized balance of deferred rent associated with the previously leased premises will be aggregated with the total expected rental payments, and will be amortized on a straight-line basis over the term of the new lease.

On August 16, 2012, as part of the acquisition of Meta Health Technology, the Company assumed a lease agreement for office space of approximately 10,000 square feet in size, at 330 Seventh Ave., New York, New York. This lease term expired on August 31, 2014. During the third quarter of fiscal 2014, the Company relocated its New York office to 105 Madison Avenue, New York, New York. The lease commenced upon taking possession of the space and ends 63 months thereafter. The provisions of the lease for the new office space of 10,350 square feet provide for rent abatement for the first two months of the lease term. Upon taking possession of the premises, the rent abatement was aggregated with the total expected rental payments, and is being amortized on a straight-line basis over the term of the lease.

The Company has capital leases to finance office equipment and maintenance services purchases. The balance of fixed assets acquired under these capital leases is $1,515,000 and $261,000 as of January 31, 2015 and 2014, respectively, and the balance of accumulated depreciation is $494,000 and $76,000 for the respective periods. The amortization expense of leased assets is included in depreciation expense.

Debt Issuance Costs

Costs related to the issuance of debt are capitalized and amortized to interest expense on a straight-line basis, which is not materially different from the effective interest method, over the term of the related debt.

Interest Rate Swap

In December 2013, the Company entered into an interest rate swap agreement to hedge against interest rate exposure of its variable rate debt obligation. The interest rate swap settles any accrued interest for cash on the first day of each calendar month until expiration. At such dates, the differences to be paid or received on the interest rate swaps will be included in interest expense. The interest rate swap qualifies for cash flow hedge accounting treatment and as such, the change in the fair values of the interest rate swap is recorded on the Company's consolidated balance sheet as an asset or liability with the effective portion of the interest rate swaps' gains or losses reported as a component of other comprehensive loss and the ineffective portion reported in loss.

The fair value of the Company's interest rate swap is based on Level 2 inputs as described in ASC Topic 820, Fair Value Measurements and Disclosures, which include observable inputs such as dealer-quoted prices for similar assets or liabilities, and represents the estimated amount the Company would receive or pay to terminate the agreement taking into consideration various factors, including current interest rates, credit risk and counterparty credit risk.

During the third quarter of fiscal 2014, the interest rate swap was terminated prior to its maturity, and losses accumulated in other comprehensive loss were reclassified into earnings.

Impairment of Long-Lived Assets

The Company reviews the carrying value of the long-lived assets whenever facts and circumstances exist that would suggest that assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation are changes in market position and profitability. If facts and circumstances are present which may indicate impairment is probable, the Company will prepare a projection of the undiscounted cash flows of the specific asset and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair value.

Capitalized Software Development Costs

Software development costs associated with the planning and designing phase of software development, including coding and testing activities necessary to establish technological feasibility, are classified as research and development and are expensed as incurred. Once technological feasibility has been determined, a portion of the costs incurred in development, including coding, testing, and quality assurance, are capitalized and subsequently reported at the lower of unamortized cost or net realizable value. The Company capitalized such costs, including interest, of $620,000, $614,000 and $2,000,000 in fiscal 2014, 2013 and 2012, respectively. The Company acquired $2,017,000 of internally developed software in 2014 through the acquisition of Unibased, and $3,646,000 in 2012 through the acquisition of Meta, which is described in Note 3 - Acquisitions.

Amortization for the Company's legacy software systems is provided on a solution-by-solution basis over the estimated economic life of the software, typically five years, using the straight-line method. Amortization commences when a solution is available for general release to clients. Acquired internally developed software from the Interpoint, Meta, and Unibased acquisitions is amortized using the straight-line method.

Amortization expense on all internally developed software was $3,678,000, $3,192,000 and $2,659,000 in fiscal 2014, 2013 and 2012, respectively, which included in the consolidated statements of operations as follows:



	Fiscal Year
Amortization expense on internally developed software included in:	2014		2013		2012
Cost of systems sales	$	3,352,000	$	2,769,000	$	2,435,000
Cost of software as a service	326,000		423,000		224,000
Total amortization expense on internally developed software	$	3,678,000	$	3,192,000	$	2,659,000

Research and development expense, net of capitalized amounts, was $9,756,000, $7,088,000 and $2,948,000 in fiscal 2014, 2013 and 2012, respectively.

Fair Value of Financial Instruments

The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. The carrying amount of the Company’s long-term debt approximates fair value since the interest rates being paid on the amounts approximate the market interest rate. Long-term debt and the interest rate swap are classified as Level 2. The initial fair value of royalty liability and warrants liability was determined by management with the assistance of an independent third-party valuation specialist, and by management thereafter. The fair value of warrants liability as of January 31, 2015 was also determined by management with the assistance of an independent third-party valuation specialist using a binomial model. The fair value of the royalty liability is determined based on the probability-weighted revenue scenarios for the Looking Glass® Clinical Analytics solution licensed from Montefiore Medical Center (discussed below). The contingent consideration for the royalty liability and warrants liability are classified as Level 3.

Revenue Recognition

The Company derives revenue from the sale of internally developed software either by licensing or by software as a service, through the direct sales force or through third-party resellers. Licensed, locally-installed, clients utilize the Company’s support and maintenance services for a separate fee, whereas SaaS fees include support and maintenance. The Company also derives revenue from professional services that support the implementation, configuration, training, and optimization of the applications. Additional revenues are also derived from reselling third-party software and hardware components.

The Company recognizes revenue in accordance with ASC 985-605, Software-Revenue Recognition and ASC 605-25 Revenue Recognition — Multiple-element arrangements. The Company commences revenue recognition when the following criteria all have been met:


•	Persuasive evidence of an arrangement exists,


•	Delivery has occurred or services have been rendered,


•	The arrangement fees are fixed or determinable, and


•	Collection is considered probable.

If we determine that any of the above criteria have not been met, we will defer recognition of the revenue until all the criteria have been met. Maintenance and support and SaaS agreements entered into are generally non-cancelable, or contain significant penalties for early cancellation, although clients typically have the right to terminate their contracts for cause if the Company fails to perform material obligations. However, if non-standard acceptance periods or non-standard performance criteria, cancellation or right of refund terms are required, revenue is recognized upon the satisfaction of such criteria, as applicable.

Revenues from resellers are recognized gross of royalty payments to resellers.

Multiple Element Arrangements

The Company applies the provisions of Accounting Standards Update No. 2009-13, Revenue Recognition (Topic 605), “Multiple-Deliverable Revenue Arrangements — a consensus of the FASB Emerging Issues Task Force” (“ASU 2009-13”). ASU 2009-13 amended the accounting standards for revenue recognition for multiple deliverable revenue arrangements to:


•	Provide updated guidance on how deliverables of an arrangement are separated, and how consideration is allocated;


•	Eliminate the residual method and require entities to allocate revenue using the relative selling price method and;


•	Require entities to allocate revenue to an arrangement using the estimated selling price (“ESP”) of deliverables if it does not have vendor specific objective evidence (“VSOE”) or third party evidence (“TPE”) of selling price.

Terms used in evaluation are as follows:


•	VSOE — the price at which an element is sold as a separate stand-alone transaction


•	TPE — the price of an element, charged by another company that is largely interchangeable in any particular transaction


•	ESP — the Company’s best estimate of the selling price of an element of the transaction

The Company follows accounting guidance for revenue recognition of multiple-element arrangements to determine whether such arrangements contain more than one unit of accounting. Multiple-element arrangements require the delivery or performance of multiple solutions, services and/or rights to use assets. To qualify as a separate unit of accounting, the delivered item must have value to the client on a stand-alone basis. Stand-alone value to a client is defined in the guidance as those that can be sold separately by any vendor or the client could resell the item on a stand-alone basis. Additionally, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item or items must be considered probable and substantially in the control of the vendor.

The Company has a defined pricing methodology for all elements of the arrangement and proper review of pricing to ensure adherence to Company policies. Pricing decisions include cross-functional teams of senior management, which uses market conditions, expected contribution margin, size of the client’s organization, and pricing history for similar solutions when establishing the selling price.

Software as a Service

The Company uses ESP to determine the value for a software as a service arrangement as the Company cannot establish VSOE and TPE is not a practical alternative due to differences in functionality from the Company's competitors. Similar to proprietary license sales, pricing decisions rely on the relative size of the client purchasing the solution, and include calculating the equivalent value of maintenance and support on a present value basis over the term of the initial agreement period. Typically revenue recognition commences upon client go-live on the system, and is recognized ratably over the contract term.

System Sales

The Company uses the residual method to determine fair value for proprietary software license sold in a multi-element arrangement as the Company cannot establish fair value for all of the undelivered elements. Typically pricing decisions for proprietary software rely on the relative size and complexity of the client purchasing the solution. Third-party components are resold at prices based on a cost plus margin analysis. The proprietary software and third-party components do not need any significant modification to achieve its intended use. When these revenues meet all the criteria for revenue recognition, and are determined to be separate units of accounting revenue is recognized. Typically this is upon shipment of components or electronic download of software. Proprietary licenses are perpetual in nature, and license fees do not include rights to version upgrades, fixes or service packs.

Maintenance and Support Services

The maintenance and support components are not essential to the functionality of the software and clients renew maintenance contracts separately from software purchases at renewal rates materially similar to the initial rate charged for maintenance on the initial purchase of software. The Company uses VSOE of fair value to determine fair value of maintenance and support services. Rates are set based on market rates for these types of services, and the Company’s rates are comparable to rates charged by its competitors, which is based on the knowledge of the marketplace by senior management. Generally, maintenance and support is calculated as a percentage of the list price of the proprietary license being purchased by a client. Clients have the option of purchasing additional annual maintenance service renewals each year for which rates are not materially different from the initial rate, but typically include a nominal rate increase based on the consumer price index. Annual maintenance and support agreements entitle clients to technology support, upgrades, bug fixes and service packs.

Term Licenses

We cannot establish VSOE fair value of the undelivered element in term license arrangements. However, as the only undelivered element is post-contract customer support, the entire fee is recognized ratably over the contract term. Typically, revenue recognition commences once the client goes live on the system. Similar to proprietary license sales, pricing decisions rely on the relative size of the client purchasing the solution. The software portion of our coding and clinical documentation improvement solutions generally does not require material modification to achieve their contracted function.

Professional Services

Professional services components that are not essential to the functionality of the software, from time to time, are sold separately by the Company. Similar services are sold by other vendors, and clients can elect to perform similar services in-house. When professional services revenues are a separate unit of accounting, revenues are recognized as the services are performed.

Professional services components that are essential to the functionality of the software, and are not considered a separate unit of accounting, are recognized in revenue ratably over the life of the client, which approximates the duration of the initial contract term. The Company defers the associated direct costs for salaries and benefits expense for professional services contracts. These deferred costs will be amortized over the identical term as the associated SaaS revenues. As of January 31, 2015 and 2014, the Company had deferred costs of $570,000 and $331,000, respectively, net of accumulated amortization of $275,000 and $110,000, respectively. Amortization expense of these costs was $166,000, $110,000 and $35,000 in fiscal 2014, 2013 and 2012, respectively.

The Company uses VSOE of fair value based on the hourly rate charged when services are sold separately, to determine fair value of professional services. The Company typically sells professional services on an hourly-fee basis. The Company monitors projects to assure that the expected and historical rate earned remains within a reasonable range to the established selling price.

Concentrations

Financial instruments, which potentially expose the Company to concentrations of credit risk, consist primarily of accounts receivable. The Company’s accounts receivable are concentrated in the healthcare industry. However, the Company’s clients typically are well-established hospitals, medical facilities, or major health information systems companies that resell the Company’s solutions that have good credit histories. Payments from clients have been received within normal time frames for the industry. However, some hospitals and medical facilities have experienced significant operating losses as a result of limits on third-party reimbursements from insurance companies and governmental entities and extended payment of receivables from these entities is not uncommon.

To date, the Company has relied on a limited number of clients and remarketing partners for a substantial portion of its total revenues. The Company expects that a significant portion of its future revenues will continue to be generated by a limited number of clients and its remarketing partners.

The Company currently buys all of its hardware and some major software components of its healthcare information systems from third-party vendors. Although there are a limited number of vendors capable of supplying these components, management believes that other suppliers could provide similar components on comparable terms.

Business Combinations

The assets acquired, liabilities assumed, and contingent consideration are recorded at their fair value on the acquisition date with subsequent changes recognized in earnings. These estimates are inherently uncertain and are subject to refinement. Management develops estimates based on assumptions as a part of the purchase price allocation process to value the assets acquired and liabilities assumed as of the business combination date. As a result, during the preliminary purchase price measurement period, which may be up to one year from the business combination date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. After the preliminary purchase price measurement period, the Company will record adjustments to assets acquired or liabilities assumed subsequent to the purchase price measurement period in operating expenses in the period in which the adjustments were determined.

The Company records acquisition and transaction related expenses in the period in which they are incurred. Acquisition and transaction related expenses primarily consist of legal, banking, accounting and other advisory fees of third parties related to potential acquisitions.

Goodwill and Intangible Assets

Goodwill and other intangible assets were recognized in conjunction with the Interpoint, Meta, CLG, and Unibased acquisitions. Identifiable intangible assets include purchased intangible assets with finite lives, which primarily consist of internally developed software, client relationships, supplier agreements, non-compete agreements, customer contracts, and license agreement. Finite-lived purchased intangible assets are amortized over their expected period of benefit, which generally ranges from one to 15 years, using the straight-line and undiscounted expected future cash flows methods. The indefinite-lived intangible asset relates to the Meta trade name, which was not amortized, but tested for impairment on at least an annual basis. In fiscal 2014, Meta trade name was deemed impaired and its corresponding balance was fully written off (see Note 7 - Goodwill and Intangible Assets).

The Company assesses the useful lives and possible impairment of existing recognized goodwill and intangible assets when an event occurs that may trigger such a review. Factors considered important which could trigger a review include:


•	significant under performance relative to historical or projected future operating results;


•	significant changes in the manner of use of the acquired assets or the strategy for the overall business;


•	identification of other impaired assets within a reporting unit;


•	disposition of a significant portion of an operating segment;


•	significant negative industry or economic trends;


•	significant decline in the Company's stock price for a sustained period; and


•	a decline in the market capitalization relative to the net book value.

Determining whether a triggering event has occurred involves significant judgment by the Company.

The Company assesses goodwill annually (during the fourth quarter), or more frequently when events and circumstances, such as the ones mentioned above, occur indicating that the recorded goodwill may be impaired. The Company did not note any of the above qualitative factors, which would be considered a triggering event for impairment. In assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company assesses relevant events and circumstances that may impact the fair value and the carrying amount of a reporting unit. The identification of relevant events and circumstances and how these may impact a reporting unit's fair value or carrying amount involve significant judgments by management. These judgments include the consideration of macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, events which are specific to the Company, and trends in the market price of the Company's common stock. Each factor is assessed to determine whether it impacts the impairment test positively or negatively, and the magnitude of any such impact.

The two-step goodwill impairment test requires the Company to identify its reporting units and to determine estimates of the fair values of those reporting units as of the impairment testing date. Reporting units are determined based on the organizational structure the entity has in place at the date of the impairment test. A reporting unit is an operating segment or component business unit with the following characteristics: (a) it has discrete financial information, (b) segment management regularly reviews its operating results (generally an operating segment has a segment manager who is directly accountable to and maintains regular contact with the chief operating decision maker to discuss operating activities, financial results, forecasts, or plans for the segment), and (c) its economic characteristics are dissimilar from other units (this contemplates the nature of the products and services, the nature of the production process, the type or class of customer for the products and services, and the methods used to distribute the products and services).

The Company determined that it has one operating segment and one reporting unit.

To conduct a quantitative two-step goodwill impairment test, the fair value of the reporting unit is first compared to its carrying value. If the reporting unit's carrying value exceeds its fair value, the Company performs the second step and records an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company estimates the fair value of its reporting unit using a blend of market and income approaches. The market approach consists of two separate methods, including reference to the Company's market capitalization, as well as the guideline publicly traded company method. The market capitalization valuation method is based on an analysis of the Company's stock price on and around the testing date, plus a control premium. The guideline public company method was made by reference to a list of publicly traded software companies providing services to healthcare organizations, as determined by management. The market value of common equity for each comparable company was derived by multiplying the price per share on the testing date by the total common shares outstanding, plus a control premium. Selected valuation multiples are then determined and applied to appropriate financial statistics based on the Company's historical and forecasted results. The Company estimates the fair value of its reporting unit using the income approach, via discounted cash flow valuation models which include, but are not limited to, assumptions such as a “risk-free” rate of return on an investment, the weighted average cost of capital of a market participant, and future revenue, operating margin, working capital and capital expenditure trends. Determining the fair values of reporting units and goodwill includes significant judgment by management, and different judgments could yield different results.

The Company performed its annual assessment of goodwill during the fourth quarter of fiscal 2014, using the two-step approach described above. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit with its carrying amount, including goodwill. Based on the analysis performed for step one, the fair value of the reporting unit exceeded the carrying amount of the reporting unit, including goodwill, and, therefore, an impairment loss was not recognized. As the Company passed step one of the analysis, step two was not required.

Severances

From time to time, we will enter into termination agreements with associates that may include supplemental cash payments, as well as contributions to health and other benefits for a specific time period subsequent to termination. In fiscal 2014, 2013 and 2012, we incurred $666,000, $384,000 and $866,000 in severance expenses. At January 31, 2015 and 2014, we had accrued for $159,000 and zero in severances, respectively.

Equity Awards

The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite vesting period. The Company incurred total annual compensation expense related to stock-based awards of $1,934,000, $1,661,000 and $956,000 in fiscal 2014, 2013 and 2012, respectively.

The fair value of the stock options granted in fiscal 2014, 2013 and 2012 was estimated at the date of grant using a Black-Scholes option pricing model. Option pricing model input assumptions such as expected term, expected volatility, and risk-free interest rate impact the fair value estimate. Further, the forfeiture rate impacts the amount of aggregate compensation. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor, expected term, and forfeiture rates). Future grants of equity awards accounted for as stock-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards.

The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market close price per share on the day of grant. The Company expenses the compensation cost of these awards as the restriction period lapses, which is typically a one-year service period to the Company.

Common Stock Warrants

As of January 31, 2014, the fair value of the common stock warrants was computed using the Black-Scholes option pricing model. The estimated fair value of the warrant liabilities as of January 31, 2015 was computed using Monte-Carlo simulations. Both valuations were based on assumptions regarding annual volatility, risk-free rate, dividend yield and expected life. The models also include assumptions to account for anti-dilutive provisions within the warrant agreement.

Comprehensive Loss

Total other comprehensive income (loss) for fiscal years 2014, 2013 and 2012 was $111,000, $(111,000) and zero, respectively. Total other comprehensive income (loss) relates to the change in the unrealized loss on the Company's interest rate swap arrangement. The Company's interest rate swap arrangement is further described in Note 6 - “Debt”.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. See Note 8 - “Income Taxes” for further details.

The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not to be sustained upon examination by tax authorities. At January 31, 2015, the Company believes it has appropriately accounted for any uncertain tax positions. As part of the Meta acquisition, the Company assumed a current liability for an uncertain tax position. The Company has recorded zero and $181,000 of reserves for uncertain tax positions and corresponding interest and penalties as of January 31, 2015 and January 31, 2014, respectively.

Net Loss Per Common Share

The Company presents basic and diluted earnings per share (“EPS”) data for its common stock. Basic EPS is calculated by dividing the net loss attributable to shareholders of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to shareholders and the weighted average number of shares of common stock outstanding adjusted for the effects of all dilutive potential common shares comprised of options granted, unvested restricted stocks, warrants and convertible preferred stock. Potential common stock equivalents that have been issued by the Company related to outstanding stock options, unvested restricted stock and warrants are determined using the treasury stock method, while potential common shares related to Series A Convertible Preferred Stock are determined using the “if converted” method.

The Company's unvested restricted stock awards and Series A Convertible Preferred stock are considered participating securities under ASC 260, “Earnings Per Share” which means the security may participate in undistributed earnings with common stock. The Company's unvested restricted stock awards are considered participating securities because they entitle holders to non-forfeitable rights to dividends or dividend equivalents during the vesting term. The holders of the Series A Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of common stock were to receive dividends, other than dividends in the form of common stock. In accordance with ASC 260, a company is required to use the two-class method when computing EPS when a company has a security that qualifies as a “participating security.” The two-class method is an earnings allocation formula that determines EPS for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stock holders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding for the period. Diluted EPS for the Company's common stock is computed using the more dilutive of the two-class method or the if-converted method.

In accordance with ASC 260, securities are deemed to not be participating in losses if there is no obligation to fund such losses. For the years ended January 31, 2015, 2014 and 2013, the unvested restricted stock awards and the Series A Preferred Stock were not deemed to be participating since there was a net loss from operations for the years ended January 31, 2015, 2014 and 2013. As of January 31, 2015 , 2014 and 2013, there were 2,949,995, 2,949,995 and 3,999,995 shares of preferred stock outstanding, respectively, each share is convertible into one share of the Company's common stock. For the years ended January 31, 2015, 2014 and 2013, the Series A Convertible Preferred Stock would have an anti-dilutive effect if included in Diluted EPS and, therefore, was not included in the calculation. As of January 31, 2015, 2014 and 2013, there were 120,306, 29,698 and 137,325 unvested restricted shares of common stock outstanding, respectively. These unvested restricted shares were excluded from the calculation as their effect would have been antidilutive.

The following is the calculation of the basic and diluted net loss per share of common stock:



				Fiscal Year
	2014			2013			2012
Net loss	$	(12,011,457	)	$	(11,717,190	)	$	(5,378,729	)
Less: deemed dividends on Series A Preferred Stock	(1,038,310		)	(1,180,904		)	(176,048		)
Net loss attributable to common shareholders	$	(13,049,767	)	$	(12,898,094	)	$	(5,554,777	)
Weighted average shares outstanding used in basic per common share computations	18,261,800			13,747,700			11,634,540
Stock options and restricted stock	—			—			—
Number of average shares used in diluted per common share computation	18,261,800			13,747,700			11,634,540
Basic net loss per share of common stock	$	(0.71	)	$	(0.94	)	$	(0.48	)
Diluted net loss per share of common stock	$	(0.71	)	$	(0.94	)	$	(0.48	)

Diluted loss per share exclude the effect of 2,437,323, 2,304,407 and 2,685,237 outstanding stock options in fiscal 2014, 2013 and 2012, respectively. The inclusion of these shares would be anti-dilutive. For the years ended January 31, 2015, 2014 and 2013, the outstanding common stock warrants of 1,400,000 would have an anti-dilutive effect if included in Diluted EPS and, therefore, were not included in the calculation.

Loss Contingencies

We are subject to the possibility of various loss contingencies arising in the course of business. We consider the likelihood of the loss or impairment of an asset or the incurrence of a liability as well as our ability to reasonably estimate the amount of loss in determining loss contingencies. An estimated loss contingency is accrued when it is probable that a liability has been incurred or an asset has been impaired and the amount of loss can be reasonably estimated. We regularly evaluate current information available to us to determine whether to accrue for a loss contingency and adjust any previous accrual.

Recent Accounting Pronouncements

In August 2014, the FASB issued an accounting standard update relating to disclosures of uncertainties about an entity’s ability to continue as a going concern. The update provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures in the event that there is such substantial doubt. The update will be effective for us on February 1, 2017.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This guidance is effective for us on February 1, 2017. Early adoption is not permitted. The guidance is to be applied using one of two retrospective application methods. We are currently evaluating the impact of the adoption of this accounting standard update on our internal processes, operating results, and financial reporting.

In July 2013, the FASB issued an accounting standard update relating to the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This update amends existing GAAP that required in certain cases, an unrecognized tax benefit, or portion of an unrecognized tax benefit, to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date, and retrospective application is permitted. The Company adopted this update on January 31, 2014, and it did not have a material impact on our financial statements.

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

Acquisitions

12 Months Ended

Jan. 31, 2015

Business Combinations [Abstract]

ACQUISITIONS

On August 16, 2012 the Company acquired substantially all of the outstanding stock of Meta Health Technology, Inc., a New York corporation (“Meta”). The Company paid a total purchase price of $14,790,000, consisting of cash payment of $13,288,000 and the issuance of 393,086 shares of the Company's common stock at an agreed upon price price of $4.07 per share. The fair value of the common stock at the date of issuance was $3.82. For the year ended January 31, 2013, the Company incurred $1,306,000 of acquisition costs related to the Meta transaction, which were recorded in selling, general and administrative expense. These costs were primarily related to services provided by legal, financial, and accounting professional advisors and severances. As of October 31, 2012, the Company had acquired 100% of Meta’s outstanding shares.

The acquisition of Meta represents the Company's on-going growth strategy, and is reflective of the solutions development process, which is led by the needs and requirements of clients and the marketplace in general. The Meta suite of solutions, when bundled with the Company's existing solutions, will help current and prospective clients better prepare for compliance with the ICD-10 transition. The Company believes that the integration of business analytics solutions with the coding solutions acquired in this transaction will position the Company to address the complicated issues of clinical analytics as clients prepare for the proposed changes in commercial and governmental payment models.

The purchase price is subject to certain adjustments related principally to the delivered working capital level, which was settled for $394,000 in the fourth quarter of fiscal 2013, and indemnification provisions. Under the acquisition method of accounting, the purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date as follows:



	Balance at August 16, 2012
Assets purchased:
Cash	$	1,126,000
Accounts receivable	2,300,000
Property and equipment	133,000
Other assets	513,000
Client relationships	4,464,000
Internally-developed software	3,646,000
Trade name (2)	1,588,000
Supplier agreements	1,582,000
Covenants not to compete	720,000
Goodwill (1), (2)	8,073,000
Total assets purchased	$	24,145,000
Liabilities assumed:
Accounts payable and accrued liabilities	1,259,000
Deferred revenue obligation, net	3,494,000
Deferred tax liabilities	4,602,000
Net assets acquired	$	14,790,000
Consideration:
Company common stock	$	1,502,000
Cash paid	13,288,000
Total consideration	$	14,790,000

_______________


(1)	Goodwill represents the excess of purchase price over the estimated fair value of net tangible and intangible assets acquired, which is not deductible for tax purposes.


(2)	See Note 7 - Goodwill and Intangible Assets for further changes in fiscal 2013. In fiscal 2014, Meta trade name was deemed impaired and its corresponding balance was fully written off.

The acquired operations of Meta are consolidated with the results of the Company from August 16, 2012. Due to the new deferred tax liabilities recorded as a result of the above purchase price allocation, the Company was able to reduce its valuation allowance by $3,000,000 representing the significant deferred tax benefit recorded for the year ended January 31, 2013.

On October 25, 2013, we entered into a Software License and Royalty Agreement (the “Royalty Agreement”) with Montefiore Medical Center (“Montefiore”) pursuant to which it entered into an agreement for an exclusive, worldwide 15-year license of Montefiore’s proprietary clinical analytics platform solution, Clinical Looking Glass® (“CLG”), now known as our Looking Glass® Clinical Analytics solution. In addition, Montefiore assigned to us the existing license agreement with a customer using CLG. As consideration under the Royalty Agreement, Streamline paid Montefiore a one-time initial base royalty fee of $3,000,000, and we are obligated to pay on-going quarterly royalty amounts related to future sublicensing of CLG by Streamline. Additionally, Streamline has committed that Montefiore will receive at least an additional $3,000,000 of on-going royalty payments within the first six and one-half years of the license term.

The Montefiore agreements were accounted for as a business combination with the purchase price representing the $3,000,000 initial base royalty fee, plus the present value of the $3,000,000 on-going royalty payment commitment. The purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimate fair values as of the acquisition date as follows:



	Balance at October 25, 2013
Assets purchased:
License agreement	$	4,431,000
Existing customer relationship	408,000
Covenant not to compete	129,000
Working capital	124,000
Other assets	25,000
Goodwill (1)	108,000
Total assets purchased	$	5,225,000
Consideration:
Cash paid	$	3,000,000
Future royalty commitment	2,225,000
Total consideration	$	5,225,000

_______________


(1)	Goodwill represents the excess of purchase price over the estimated fair value of net tangible and intangible assets acquired, which is not deductible for tax purposes.

On February 3, 2014, we completed the acquisition of Unibased Systems Architecture, Inc. (“Unibased”), a provider of patient access solutions, including enterprise scheduling and surgery management software, for healthcare organizations throughout the United States, pursuant to an Agreement and Plan of Merger dated January 16, 2014 (the “Merger Agreement”) for a total purchase price of $6,500,000, subject to net working capital and other customary adjustments. A portion of the total purchase price was withheld in escrow as described in the Merger Agreement for certain transaction and indemnification expenses.

Pursuant to the Merger Agreement, we acquired all of the issued and outstanding common stock of Unibased, and Unibased became a wholly-owned subsidiary of Streamline. Under the terms of the Merger Agreement, Unibased stockholders received cash for each share of Unibased common stock held. The preliminary purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date as follows:



	Balance at February 3, 2014
Assets purchased:
Cash	$	59,000
Accounts receivable (2)	221,000
Other assets	61,000
Internally-developed software	2,017,000
Client relationships	647,000
Trade name	26,000
Goodwill (1)	4,251,000
Total assets purchased	7,282,000
Liabilities assumed:
Accounts payable and accrued liabilities	362,000
Deferred revenue obligation, net	793,000
Deferred income taxes	9,000
Net assets acquired	$	6,118,000
Cash paid	$	6,118,000

_______________


(1)	Goodwill represents the excess of purchase price over the estimated fair value of net tangible and intangible assets acquired, which is not deductible for tax purposes.


(2)	During the fourth quarter of fiscal 2014, the Company recorded an immaterial correction of an error to reduce the accounts receivable acquired from Unibased by $266,000, with the offset to goodwill.

In fiscal 2014, revenues and net loss from acquired Unibased operations totaled $1,849,000 and $414,000, respectively. The operating results of Unibased are not material for proforma disclosure.

On May 6, 2014, we signed a definitive asset purchase agreement with CentraMed, Inc., a California corporation (“CentraMed”). The definitive agreement provided for the purchase of substantially all of CentraMed’s assets related to its business of providing healthcare analytics and consulting services to hospitals, physicians and other providers. The agreement also provided that at closing we would pay $4.8 million in cash for such assets and it included detailed representations, warranties and covenants, as well as indemnification and termination provisions customary for transactions of this type. On January 12, 2015, Streamline terminated the definitive agreement in accordance with our termination rights under the agreement. We incurred no termination penalties under the agreement as a result of the termination.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

+ Details

Derivative Liabilities	12 Months Ended
Derivative Liabilities	Jan. 31, 2015
Other Liabilities Disclosure [Abstract]
DERIVATIVE LIABILITIES	DERIVATIVE LIABILITIES As discussed further in Note 15 - Private Placement Investment, in conjunction with the private placement investment, the Company issued common stock warrants exercisable for up to 1,200,000 of common stock at an exercise price of $3.99 per share. The warrants were initially classified in stockholders' equity as additional paid-in capital at the allocated amount, net of allocated transaction costs, of $1,425,000. Effective October 31, 2012, upon shareholder approval of anti-dilution provisions that reset the warrant's exercise price if a dilutive issuance occurs, the warrants were reclassified as non-current derivative liabilities. The fair value of the warrants was $4,139,000 at October 31, 2012, with the difference between the fair value and carrying value recorded to additional paid-in capital. Effective as of the reclassification as derivative liabilities, the warrants are re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period as a credit or charge to miscellaneous income (expense). The fair value of the warrants at January 31, 2015 and 2014 was $1,834,000 and $4,117,000, respectively. The change in fiscal 2014, 2013 and 2012 reflects $2,283,000 and $141,000 and $489,000 respectively, of miscellaneous income recognized in the consolidated statements of operations as a result of decreases in the fair value of the warrants. The change in fiscal 2013 also reflects a valuation adjustment that increased the warrant liability by $609,000, offset by decreases in Series A Preferred Stock (see Note 15) of $197,000 and additional paid-in capital of $412,000. The estimated fair value of the warrant liabilities as of January 31, 2015 was computed using Monte-Carlo simulations based on the following assumptions: annual volatility of 55%; risk-free rate of 0.8%, dividend yield of 0.0% and expected life of three years. The model also included assumptions to account for anti-dilutive provisions within the warrant agreement. The estimated fair value of the warrant liabilities as of January 31, 2014 was computed using the Black-Scholes option pricing model based on the following assumptions: annual volatility of 58.24%; risk-free rate of 1.07%, dividend yield of 0.0% and expected life of four years During fiscal 2013, the Company recorded an immaterial correction of an error regarding the valuation of its common stock warrants originated during the third quarter of fiscal 2012 in conjunction with its private placement investment. The Company concluded there was a cumulative $19,000 overstatement of the loss before income taxes on its consolidated statement of operations for the fiscal year ended January 31, 2013, as previously reported. The aforementioned cumulative $19,000 overstatement has been recorded in the consolidated statement of operations for fiscal 2013. The January 31, 2013 consolidated balance sheet, as previously reported, reflects a $51,000 overstatement of deferred financing costs, a cumulative $150,000 understatement of deemed dividends on Series A Preferred Stock, and a $609,000 overstatement of the Series A Preferred Stock and additional paid-in capital. These aforementioned consolidated balance sheet adjustments have been recorded on the January 31, 2014 consolidated balance sheet as presented herein. The Company concluded that the impact of the corrections were not quantitatively and qualitatively material to the prior and current fiscal years.

Operating Leases

12 Months Ended

Jan. 31, 2015

Leases [Abstract]

OPERATING LEASES

The Company rents office and data center space and equipment under non-cancelable operating leases that expire at various times through fiscal year 2022. Future minimum lease payments under non-cancelable operating leases for the next five fiscal years and thereafter are as follows:



	Facilities		Equipment		Fiscal Year Totals
2015	$	1,035,000	$	5,000	$	1,040,000
2016	969,000		2,000		971,000
2017	1,007,000		—		1,007,000
2018	1,039,000		—		1,039,000
2019	967,000		—		967,000
Thereafter	1,468,000		—		1,468,000
Total	$	6,485,000	$	7,000	$	6,492,000

Rent and leasing expense for facilities and equipment was $1,652,000, $1,333,000 and $965,000 for fiscal years 2014, 2013 and 2012, respectively.

- Definition

The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.

+ References+ Details

Debt

12 Months Ended

Jan. 31, 2015

Debt Disclosure [Abstract]

DEBT

Term Loan and Line of Credit

On August 16, 2012, the Company amended the subordinated credit agreement with Fifth Third Bank, whereby Fifth Third Bank provided the Company with a $5,000,000 revolving line of credit, a $5,000,000 senior term loan and a $9,000,000 subordinated term loan, a portion of which was used to refinance the previously outstanding $4,120,000 subordinated term loan with Fifth Third Bank. Additionally, as part of the refinancing in August 2012, the Company mutually agreed to settle the success fee included in the previous subordinated term loan for $700,000. The difference between the $233,000 success fee accrued through the date of the amendment and the amount paid was recorded to deferred financing costs and amortized over the term of the amended loan. The Company paid a commitment fee in connection with the senior term loan of $75,000, which was included in deferred financing costs.

We were required to pay a success fee in accordance with the amended subordinated term loan, which was recorded in interest expense as accrued over the term of the loan. The success fee was due on the date the entire principal balance of the loan became due (August 16, 2014). The success fee was accrued in accordance with the terms of the loan in an amount necessary to provide the lender a 17% internal rate of return through the date the success fee became due. The accrued success fee of $1,124,000 was paid when the subordinated term loan was paid in full, as described below.

In December 2013, we amended and restated our previously outstanding senior credit agreement and amended the subordinated credit agreement to increase the senior term loan to $8,500,000, reduce the interest rates, and extend the maturity of the senior term loan and the revolving line of credit to December 1, 2018 and December 1, 2015, respectively. In January 2014, we paid the subordinated term loan in full. The outstanding senior term loan was secured by substantially all of our assets. The senior term loan principal balance was payable in monthly installments of $101,000, which started in January 2014 and would have continued through the maturity date, with the full remaining unpaid principal balance due at maturity. Borrowings under the senior term loan bore interest at a rate of LIBOR plus 5.25%. However, as a result of our interest rate swap, the interest rate was fixed at 6.42% until October 27, 2014, when the interest rate swap agreement was terminated. Accrued and unpaid interest on the senior term loan was due monthly through maturity. We paid $116,000 in closing fees in connection with this senior term loan, which was recorded as a debt discount and amortized to interest expense over the term of the loan using the effective interest method.

Borrowings under the revolving line of credit bore interest at a rate equal to LIBOR plus 3.50%. A commitment fee of 0.40% was on the unused revolving line of credit balance, and was payable quarterly.

On November 21, 2014, we entered into a Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, N.A., as administrative agent, and other lender parties thereto. Pursuant to the Credit Agreement, the lenders agreed to provide a $10,000,000 senior term loan and a $5,000,000 revolving line of credit to our primary operating subsidiary. Amounts outstanding under the Credit Agreement bear interest at either LIBOR or the base rate, as elected by the Company, plus an applicable margin. Subject to the Company’s leverage ratio, the applicable LIBOR rate margin varies from 4.25% to 5.25%, and the applicable base rate margin varies from 3.25% to 4.25%. Pursuant to the terms of the amendment to the Credit Agreement entered into as of April 15, 2015, going forward the applicable LIBOR rate margin will vary from 4.25% to 6.25%, and the applicable base rate margin will vary from 3.25% to 5.25%. The term loan and line of credit mature on November 21, 2019 and provide support for working capital, capital expenditures and other general corporate purposes, including permitted acquisitions. At closing, the Company repaid indebtedness under its prior credit facility using approximately $7,400,000 of the proceeds provided by the term loan. The prior credit facility with Fifth Third Bank was terminated concurrent with the entry of the Credit Agreement and unamortized debt financing costs and discount of $315,000 associated with the terminated debt was included in loss on early extinguishment of debt. Financing costs of $401,000 associated with the new credit facility are being amortized over its term on a straight-line basis, which is not materially different from the effective interest method.

The Credit Agreement includes customary financial covenants, including the requirements that the Company maintain minimum liquidity and achieve certain minimum EBITDA levels. In addition, the credit facility prohibits the Company from paying dividends on the common and preferred stock. For the four-quarter period ended January 31, 2015, the required minimum EBITDA was zero. The Company obtained a waiver from its lender for non-compliance with the minimum EBITDA covenant at January 31, 2015. Concurrently, in April 2015 the Credit Agreement was amended to increase the applicable LIBOR rate margin, which will vary from 4.25% to 6.25%, and to reset the financial covenants. As such, the Company is required to maintain minimum liquidity of at least (i) $5,000,000 through April 15, 2015, (ii) $6,500,000 from April 16, 2015 through and including July 30, 2015, (iii) $7,000,000 from July 31, 2015 through and including January 30, 2016, and (iv) $7,500,000 from January 31, 2016 through and including the maturity date of the credit facility.

The following table shows our future minimum EBITDA covenant thresholds, as modified by the amendment to the Credit Agreement:



For the four-quarter period ending	Minimum EBITDA
April 30, 2015	$	(2,500,000	)
July 31, 2015	(1,750,000		)
October 31, 2015	(750,000		)
January 31, 2016	500,000

For the four-quarter period ending April 30, 2016, and fiscal quarters thereafter, the minimum EBITDA will be determined within 30 days following delivery of, and based upon, the projections then most recently delivered by the Company.

As of January 31, 2015, the Company had no outstanding borrowings under the revolving line of credit, and had accrued $5,000 in unused balance commitment fees.

Note Payable

In November 2013, as part of the settlement of the earn-out consideration in connection with the Interpoint acquisition described below, we issued an unsecured, subordinated three-year note in the amount of $900,000 (“Note Payable”) that would mature on November 1, 2016 and accrued interest on the unpaid principal amount outstanding at a per annum rate equal to 8%. Annual principal payments of $300,000 were due on November 1, 2014, 2015 and 2016. At closing of the Credit Agreement with Wells Fargo described above, we repaid our indebtedness under this note using approximately $600,000 of the proceeds provided by the term loan.

Outstanding principal balances on debt consisted of the following at:



	January 31, 2015		January 31, 2014
Senior term loan (1)	$	10,000,000	$	8,298,000
Note payable	—		900,000
Capital lease	1,365,000		227,000
Total	11,365,000		9,425,000
Less: Current portion	1,282,000		1,620,000
Non-current portion of long-term debt	$	10,083,000	$	7,805,000

_______________


(1)	January 31, 2014 balance represents total principal due, therefore it is not reduced by the debt discount of $112,000. In the consolidated balance sheets, the term loan is presented net of this discount.

Future repayments of long-term debt by fiscal year consisted of the following at January 31, 2015:



	Senior Term Loan		Capital Lease (1)		Total
2015	$	500,000	$	858,000	$	1,358,000
2016	750,000		457,000		1,207,000
2017	1,000,000		93,000		1,093,000
2018	1,000,000		—		1,000,000
2019	6,750,000		—		6,750,000
Total repayments	$	10,000,000	$	1,408,000	$	11,408,000

_______________


(1)	Future minimum lease payments include principal plus interest.

Contingent Earn-Out Provision

As part of the asset purchase, Interpoint was entitled to receive additional consideration contingent upon certain financial performance measurements during a one year earn-out period commencing July 1, 2012 and ending on June 30, 2013. The earn-out consideration was calculated as twice the recurring revenue for the earn-out period recognized by the acquired Interpoint operations from specific contracts defined in the asset purchase agreement, plus one times Interpoint revenue derived from the Company's customers, less $3,500,000. The earn-out consideration was due no later than July 31, 2013 in cash or through the issuance of a note with terms identical to the terms of the Convertible Note except with respect to issue date, conversion date and prepayment date. The earn-out note restricts conversion or prepayment at any time prior to the one year anniversary of the issue date.

The Company agreed to a final earn-out and paid Interpoint an aggregate consideration consisting of $1,300,000 in cash, the issuance of 400,000 shares of Company common stock on January 1, 2014, and the Note Payable.

In November 2013, the Company agreed to a final earn-out and paid Interpoint an aggregate consideration consisting of $1,300,000 in cash, a $900,000 Note Payable, and 400,000 shares that were valued at $2,700,000 based upon the closing price of the Company's common stock on January 2, 2014. A cumulative change in value of the earn-out of $3,580,000 was recorded to miscellaneous (expense) income in fiscal 2013.

Convertible Subordinated Notes Payable, Private Placement Investment

On August 16, 2012, in connection with the $12,000,000 private placement investment (“private placement investment”) with affiliated funds and accounts of Great Point Partners, LLC, and Noro-Moseley Partners VI, L.P., and another investor, the Company issued convertible subordinated notes payable in the aggregate principal amount of $5,699,577, which upon shareholder approval, convert into up to 1,583,220 shares of Series A Preferred Stock. The allocation of the proceeds to the subordinated convertible notes resulted in a debt discount of $1,934,000, which will be amortized over the period from issue date to maturity date using the effective interest rate method. The Company recorded $112,000 of debt discount amortization in fiscal 2012. On November 1, 2012, upon shareholder approval, the convertible subordinated notes were converted into shares of Series A Preferred Stock. The convertible subordinated notes had an aggregate principal amount of $5,699,577 and converted into an aggregate of 1,583,210 shares of Preferred Stock. The Company incurred a loss upon conversion of $5,913,000 on November 1, 2012. For further detail on this transaction see also Note 15 - Private Placement Investment.

Interest Rate Swap

As of January 31, 2014, the Company maintained one effective hedging relationship via one distinct interest rate swap agreement (maturing December 1, 2020), which required the Company to pay interest at a fixed rate of 6.42% and receive interest at a variable rate. This interest rate swap agreement was designated to hedge $8,500,000 of a variable rate debt obligation. The one-month LIBOR rate on each reset date determined the variable portion of the interest rate swap for the following month. The interest rate swap settled any accrued interest for cash on the first day of each calendar month, until expiration. At such dates, the differences to be paid or received on the interest rate swap were included in interest expense. No premium or discount was incurred upon the Company entering into the interest rate swap, because the pay and receive rates on the interest rate swap represented prevailing rates for the counterparty at the time the interest rate swap was entered into.

The interest rate swap qualified for cash flow hedge accounting treatment and as such, the Company had effectively hedged its exposure to variability in the future cash flows attributable to the one-month LIBOR on its $8,500,000 of variable rate obligation. The change in the fair value of the interest rate swap was recorded on the Company’s consolidated balance sheet as an asset or liability with the effective portion of the interest rate swap’s gains or losses reported as a component of other comprehensive loss and the ineffective portion reported in earnings (interest expense). As of January 31, 2014, the Company had a fair value liability of $111,000 for the effective portion of the interest rate swap. During the third quarter of fiscal 2014, the interest rate swap was terminated prior to its maturity, and losses accumulated in other comprehensive loss were reclassified into earnings.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References+ Details

Goodwill and Intangible Assets

12 Months Ended

Jan. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

The goodwill activity is summarized as follows:



	Goodwill
Balance January 31, 2013	$	12,133,000
Goodwill acquired during the year	108,000
Adjustments to goodwill during the year	(307,000		)
Balance January 31, 2014	11,934,000
Goodwill acquired during the year	4,251,000
Balance January 31, 2015	$	16,185,000

Intangible assets, net, consist of the following:



	January 31, 2015
	Estimated Useful Life	Gross Assets		Accumulated Amortization		Net Assets
Definite-lived assets:
Trade name	1 year	$	26,000	$	26,000	$	—
Client relationships	10-15 years	5,932,000		1,548,000		4,384,000
Covenants not to compete	0.5-15 years	856,000		606,000		250,000
Supplier agreements	5 years	1,582,000		778,000		804,000
License agreement	15 years	4,431,000		369,000		4,062,000
Total		$	12,827,000	$	3,327,000	$	9,500,000



	January 31, 2014
	Estimated Useful Life	Gross Assets		Accumulated Amortization		Net Assets
Indefinite-lived assets:
Trade name	N/A	$	1,952,000	$	—	$	1,952,000
Definite-lived assets:
Client relationships	10-15 years	$	5,285,000	$	862,000	$	4,423,000
Covenants not to compete	0.5-15 years	856,000		533,000		323,000
Supplier agreements	5 years	1,582,000		461,000		1,121,000
License agreement	15 years	4,431,000		74,000		4,357,000
Total		$	14,106,000	$	1,930,000	$	12,176,000

During fiscal 2013, the Company recorded a correction of an error of the original valuation of the Meta trade name indefinite-lived intangible asset. The result of this error was an undervaluation of the trade name of $364,000, with the offset to goodwill. This balance sheet adjustment has been recorded on the January 31, 2014 consolidated balance sheet as presented herein. The Company concluded that the impact of the corrections were not quantitatively and qualitatively material to the prior and current fiscal years.

In fiscal 2014, management evaluated that the concerted effort to rebrand the Company’s solutions under a single, harmonized Looking Glass® marketing platform moving forward, eroded, in total, the value of the Meta Trade name. As a result, the Company recorded a $1,952,000 loss, which is reflected in Impairment of intangible assets on the Consolidated Statements of Operations.

Amortization over the next five fiscal years for intangible assets is estimated as follows:



	Annual Amortization Expense
2015	$	1,345,000
2016	1,298,000
2017	1,088,000
2018	863,000
2019	826,000
Thereafter	4,080,000
Total	$	9,500,000

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details

Income Taxes

12 Months Ended

Jan. 31, 2015

Income Tax Disclosure [Abstract]

INCOME TAXES

Income taxes consist of the following:



			Fiscal Year
	2014		2013			2012
Current tax benefit (expense):
Federal	$	131,816	$	(8,705	)	$	(9,391	)
State	34,611		130,048			(37,594		)
	166,427		121,343			(46,985		)
Deferred tax benefit (expense):
Federal	663,681		26,491			2,642,580
State	56,901		(47,376		)	292,942
	720,582		(20,885		)	2,935,522
Current and deferred income tax benefit	$	887,009	$	100,458		$	2,888,537

The income tax benefit for income taxes differs from the amount computed using the federal statutory income tax rate as follows:



				Fiscal Year
	2014			2013			2012
Federal tax benefit at statutory rate	$	4,385,479		$	4,018,000		$	2,810,870
State and local taxes, net of federal benefit	325,966			488,626			255,348
Change in valuation allowance	(4,030,864		)	(3,659,160		)	2,000,295
Permanent items:
Loss from conversion of notes payable	—			—			(1,937,411		)
Incentive stock options	(421,366		)	(343,117		)	—
Transaction costs	(5,291		)	(78,476		)	(339,320		)
Change in fair value of warrants liability	776,337			(159,249		)	166,408
Other	(44,719		)	(351,857		)	(45,540		)
Reserve for uncertain tax position	164,127			(11,642		)	—
Other	(262,660		)	197,333			(22,113		)
Income tax benefit	$	887,009		$	100,458		$	2,888,537

The Company provides deferred income taxes for temporary differences between assets and liabilities recognized for financial reporting and income tax purposes. The income tax effects of these temporary differences and credits are as follows:



	January 31,
	2015			2014
Deferred tax assets:
Allowance for doubtful accounts	$	245,252		$	98,661
Deferred revenue	372,275			19,561
Accruals	174,658			351,827
Net operating loss carryforwards	14,905,174			7,763,718
Stock compensation expense	438,659			362,145
Property and equipment	—			147,691
AMT credit	102,144			102,144
Other	8,912			62,783
Total deferred tax assets	16,247,074			8,908,530
Valuation allowance	(12,554,242		)	(7,666,626		)
Net deferred tax assets	3,692,832			1,241,904
Deferred tax liabilities:
Property and Equipment	(21,755		)	—
Definite-lived intangible assets	(3,671,077		)	(1,241,904		)
Indefinite-lived intangibles	(9,575		)	(720,581		)
Total deferred tax liabilities	(3,702,407		)	(1,962,485		)
Net deferred tax liabilities	$	(9,575	)	$	(720,581	)

At January 31, 2015, the Company had U.S. federal net operating loss carry forwards of $40,944,000, which expire at various dates through fiscal 2034. The Company also has an Alternative Minimum Tax net operating loss carry forward of $40,944,000, which has an unlimited carry forward period. The Company also had state net operating loss carry forwards of $20,710,000, which expire on or before fiscal 2034.

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. The Company established a valuation allowance of $12,554,000, $7,667,000 and $7,835,000 at January 31, 2015, 2014 and 2013, respectively. The increase in the valuation allowance of $4,887,000 was driven primarily by losses incurred during the year ended January 31, 2015. Management believes it is more likely than not the Company will realize the remaining deferred tax assets, net of existing valuation allowances, in future years.

Due to the reporting requirements of ASC 718, $1,592,000, tax effected $588,000 of the net operating loss carryforward is not recorded on the Company’s balance sheet because the loss was created by the tax benefits of stock option exercises, which cannot be recognized for book purposes until the benefit has been realized by actually reducing taxes payable. When recognized, the tax benefit of these losses will be accounted for as a credit to additional paid in capital rather than a reduction of the income tax provision.

The Company and its subsidiaries are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions. The Company has concluded all U.S. federal tax matters for years through January 31, 2010. All material state and local income tax matters have been concluded for years through January 31, 2009.

The Company has recorded a reserve, including interest and penalties, for uncertain tax positions of zero and $181,000 as of January 31, 2015 and January 31, 2014, respectively. As of January 31, 2015 and 2014, the Company had zero and $60,000, respectively, of accrued interest and penalties associated with unrecognized tax benefits. In fiscal 2012, a reserve was recorded in purchase accounting as part of the Meta acquisition on August 16, 2012. In fiscal 2014, this reserve was reversed due to the lapses in statutes of limitations, which resulted in a $181,000 tax benefit.

A reconciliation of the beginning and ending amounts of gross unrecognized tax benefits (excluding interest and penalties) is as follows:



	2014			2013			2012
Beginning of fiscal year	$	121,000		$	122,000		$	—
Additions for tax positions of prior years	—			—			122,000
Reductions for tax positions of prior years	—			(1,000		)	—
Reductions attributable to lapse of statute of limitations	(121,000		)	—			—
End of fiscal year	$	—		$	121,000		$	122,000

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

Employee Retirement Plan	12 Months Ended
Employee Retirement Plan	Jan. 31, 2015
Employee Retirement Plan [Abstract]
EMPLOYEE RETIREMNET PLAN	EMPLOYEE RETIREMENT PLAN The Company has established a 401(k) retirement plan that covers all associates. Company contributions to the plan may be made at the discretion of the board of directors. The Company matches 100% up to the first 4% of compensation deferred by each associate in the 401(k) plan. The total compensation expense for this matching contribution was $440,000, $370,000 and$289,000 in fiscal 2014, 2013 and 2012, respectively.

- Definition

The entire disclosure for pension and other postretirement benefits.

+ References+ Details

Employee Stock Purchase Plan	12 Months Ended
Employee Stock Purchase Plan	Jan. 31, 2015
Employee Stock Purchase Plan [Abstract]
EMPLOYEE STOCK PURCHASE PLAN	EMPLOYEE STOCK PURCHASE PLAN The Company has an Employee Stock Purchase Plan under which associates may purchase up to 1,000,000 shares of common stock. Under the plan, eligible associates may elect to contribute, through payroll deductions, up to 10% of their base pay to a trust during any plan year, i.e., July 1 through June 30 of the following year through June 30, 2013, and January 1 through December 31 of the same year beginning January 1, 2014. Semi-annually, typically in January and July of each year, the plan issues for the benefit of the employees shares of common stock at the lesser of (a) 85% of the fair market value of the common stock on the first day of the vesting period, January 1 or July 1, or (b) 85% of the fair market value of the common stock on the last day of the vesting period, June 30 or December 31 of the same year. At January 31, 2015, 97,285 shares remain that can be purchased under the plan. The Company recognized compensation expense of $14,000, $42,000 and $32,000 for fiscal years 2014, 2013 and 2012, respectively, under this plan. During fiscal 2014, 11,141 shares were purchased at the price of $4.08 per share and 9,900 shares were purchased at the price of $3.68 per share; during fiscal 2013, 36,858 shares were purchased at the price of $3.17 per share and 9,115 shares were purchased at the price of $5.67 per share. The cash received for shares purchased from the plan was $82,000 and $169,000 and $76,000 in fiscal 2014, 2013 and 2012, respectively. The purchase price at June 30, 2015, will be 85% of the lower of (a) the closing price on January 2, 2015 ($4.05) or (b) of the closing price on June 30, 2015.

Stock Based Compensation

12 Months Ended

Jan. 31, 2015

Share-based Compensation [Abstract]

STOCK BASED COMPENSATION

Stock Option Plans

The Company’s 2005 and 2013 Incentive Compensation Plans, which authorizes the Company to issue up to 4,500,000 equity awards (stock options, stock appreciation rights or “SAR’s”, and restricted stock) to directors and associates of the Company. The options granted have terms of ten years or less, and typically vest and become fully exercisable ratably over three years of continuous service to the Company from the date of grant. At January 31, 2015 and 2014, options to purchase 1,737,323 and 1,473,425 shares of the Company’s common stock have been granted, respectively, and are outstanding under the plans. There are no SAR’s outstanding under the plans. Please see "Restricted Stock" section for more information on restricted shares.

In fiscal 2014 and 2013, executive inducement grants were approved by the Company's Board of Directors pursuant to NASDAQ Marketplace Rule 5635(c)(4). The terms of the grant are nearly as practicable identical to the terms and conditions of the Company’s 2005 and 2013 Incentive Compensation Plans. For the year ended January 31, 2015, 300,000 stock options were issued, 125,694 options expired, 99,722 were forfeited, and 205,566 were exercised. For the year ended January 31, 2014, zero stock options were issued, 186,790 options were forfeited, and 105,556 were exercised. For the year ended January 31, 2013, 675,000 stock options were issued, 177,783 options expired, and 88,889 were exercised. At January 31, 2015 and 2014, there were 700,000 and 830,982 options outstanding, respectively. Please see “Restricted Stock” section for information on the restricted shares.

A summary of stock option activity is summarized as follows:



	Fiscal Year
	2014
	Options			Weighted Average Exercise Price
Outstanding — beginning of year	2,304,407			4.46
Granted	1,318,078			4.95
Exercised	(246,155		)	1.91
Expired	(168,060		)	5.31
Forfeited	(770,947		)	5.75
Outstanding — end of year	2,437,323			4.52
Exercisable — end of year	1,192,220			3.83
Aggregate intrinsic value of outstanding options at year end	$	9,798,038
Aggregate intrinsic value of exercisable options at year end	$	4,792,724

For fiscal 2014, 2013 and 2012, the weighted average grant date fair value of options granted during year was $2.90, $4.42 and $2.02, respectively, and the total intrinsic value of options exercised during the year was $990,000, $2,673,000 and $570,000, respectively.

The fiscal 2014, 2013 and 2012 stock-based compensation was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions for each fiscal year:



	2014		2013		2012
Expected life	6 years		6 years		5 years
Risk-free interest rate	1.35	%	1.81	%	0.35	%
Weighted average volatility factor	0.60		0.66		0.57
Dividend yield	—		—		—
Forfeiture rate	22	%	21	%	—



	Number of Options	Average Exercise Price			Remaining Life in Years
January 31, 2015
Outstanding	2,437,323	$	4.52	(1)	7.91
Exercisable	1,192,220	$	3.83	(2)	6.67

_______________


(1)	The exercise prices range from $1.65 to $8.17, of which 463,924 shares are between $1.65 and $2.00 per share, 519,978 shares are between $2.08 and $4.00 per share, and 1,453,421 shares are between $4.08 and $8.17 per share.


(2)	The exercise prices range from $1.65 to $8.17, of which 454,424 shares are between $1.65 and $2.00 per share, 280,667 shares are between $2.08 and $4.00 per share, and 457,129 shares are between $4.08 and $8.17 per share.

At January 31, 2015, there was $2,479,000 of compensation cost that has not yet been recognized related to non-vested stock-option awards. That cost is expected to be recognized over a remaining weighted average period of 2.0 years. The expense associated with stock option awards was $1,655,000, $1,507,000, and $664,000, respectively, for fiscal 2014, 2013 and 2012. Cash received from exercise of options and the employee stock purchase plan was $552,000, $1,356,000 and $283,000, respectively, in fiscal 2014, 2013 and 2012.

The 2005 and 2013 Incentive Compensation Plans contain change in control provisions whereby any outstanding equity awards under the plans subject to vesting, which have not fully vested as of the date of the change in control, shall automatically vest and become immediately exercisable. One of the change in control provisions is deemed to occur if there is a change in beneficial ownership, or authority to vote, directly or indirectly, securities representing 20% or more of the total of all of the Company’s then outstanding voting securities, unless through a transaction arranged by, or consummated with the prior approval of the Board of Directors. Other change in control provisions relate to mergers and acquisitions or a determination of change in control by the Company’s Board of Directors.

Restricted Stock

The Company grants restricted stock awards under the 2013 Incentive Compensation Plan to associates and members of the board of directors. The Company has also issued restricted shares as inducement grants to executives. The restrictions on the shares granted generally lapse over a one-year term of continuous employment from the date of grant. The grant date fair value per share of restricted stock, which is the stock price on the grant date, is expensed on a straight-line basis as the restriction period lapses. The shares represented by restricted stock awards are considered outstanding at the grant date, as the recipients are entitled to voting rights. A summary of restricted stock award activity for the period is presented below:



	Non-vested Number of Shares		Weighted Average Grant Date Fair Value
Non-vested balance at January 31, 2012	126,457		$	1.68
Granted	137,325		2.01
Vested	(126,457	)	1.79
Forfeited/expired	—		—
Non-vested balance at January 31, 2013	137,325		$	2.01
Granted	29,698		6.65
Vested	(137,325	)	2.01
Forfeited/expired	—		—
Non-vested balance at January 31, 2014	29,698		$	6.01
Granted	120,306		4.31
Vested	(29,698	)	6.65
Forfeited/expired	—		—
Non-vested balance at January 31, 2015	120,306		$	4.31

At January 31, 2015, there was $372,000 of compensation cost that has not yet been recognized related to restricted stock awards. That cost is expected to be recognized over a remaining period of one year or less.

The expense associated with restricted stock awards was $265,000, $112,000 and $260,000, respectively, for fiscal 2014, 2013 and 2012.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Jan. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Software as a Service The Company enters into long-term agreements to provide document imaging/management and workflow services to its healthcare clients as software as a service from a central data center. The Company guarantees specific “up-time” and “response time” performance standards, which, if not met may result in reduced revenues, as a penalty, for the month in which the standards are not met. There were no contingencies of this nature as of January 31, 2015. Litigation The Company is, from time to time, a party to various legal proceedings and claims, which arise in the ordinary course of business. Other than the matter described below, the Company is not aware of any legal matters that could have a material adverse effect on the Company’s consolidated results of operations, or consolidated financial position, or consolidated cash flows. On February 12, 2014, the Company entered into a strategic alliance agreement with CentraMed, Inc. (“CentraMed”). On May 6, 2014, the Company signed an asset purchase agreement with CentraMed. This purchase agreement provided for the Company’s purchase of substantially all of CentraMed’s assets related to its business of providing healthcare analytics and consulting services to hospitals, physicians, and other providers. The agreement provided the Company the right to terminate the agreement in a number of circumstances, including if the Company is not satisfied, in its sole and absolute discretion, with the results of its due diligence review; the Company’s senior lender does not consent to the transactions contemplated by the agreement; or the Company’s Board does not authorize the transactions contemplated by the agreement. On January 12, 2015, the Company terminated the purchase agreement in accordance with its termination rights. On March 9, 2015, CentraMed asserted claims against the Company for relief for breach of contract, misrepresentation, tortious interference with contracts and prospective economic relationships and bad faith in connection with the strategic alliance agreement and the asset purchase agreement. On March 24, 2015, the Company rejected the aforementioned claims and denied any liability to CentraMed. The Company intends to contest vigorously any action instituted against it by CentraMed. Because of the many questions of fact and law that may arise, the outcome of this matter is uncertain at this point. Based on the information available to us at present, we cannot reasonably estimate a range of loss for this matter and, accordingly, we have not accrued any liability associated with this matter.

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

Quarterly Results of Operations (Unaudited)

12 Months Ended

Jan. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

QUARTERLY RESULTS OF OPERATIONS (UNAUDITED)

The following sets forth selected unaudited quarterly financial information for fiscal 2014 and 2013. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial information have been included.



Fiscal 2014 (In thousands, except per share data):	First Quarter			Second Quarter			Third Quarter			Fourth Quarter			2014
Revenues	$	6,951		$	7,242		$	6,837		$	6,595		$	27,625
Gross profit	3,398			4,221			3,793			3,209			14,621
Operating loss (d)	(3,593		)	(2,059		)	(2,713		)	(4,948		)	(13,312		)
Net loss	(2,671		)	(2,275		)	(2,256		)	(4,810		)	(12,011		)
Less: deemed dividends on Series A Preferred Shares	(230		)	(253		)	(269		)	(286		)	(1,038		)
Net loss attributable to common shareholders	(2,901		)	(2,528		)	(2,525		)	(5,096		)	(13,050		)
Basic net loss per share (c)	(0.16		)	(0.14		)	(0.14		)	(0.28		)	(0.71		)
Diluted net loss earnings per share (c)	(0.16		)	(0.14		)	(0.14		)	(0.28		)	(0.71		)
Basic and diluted weighted average shares outstanding	18,146			18,174			18,301			18,417			18,262

Fiscal 2013 (In thousands, except per share data):	First Quarter			Second Quarter			Third Quarter			Fourth Quarter			2013
Revenues	$	6,473		$	8,773		$	6,732		$	6,517		$	28,495
Gross profit	3,297			5,536			3,597			2,887			15,317
Operating profit (loss)	(1,373		)	997			(1,140		)	(4,802		)	(6,318		)
Net loss (a)	(2,710		)	(828		)	(6,232		)	(1,947		)	(11,717		)
Less: deemed dividends on Series A Preferred Shares (b)	(342		)	(16		)	(374		)	(449		)	(1,181		)
Net loss attributable to common shareholders	(3,051		)	(844		)	(6,607		)	(2,396		)	(12,898		)
Basic net loss per share (c)	(0.24		)	(0.07		)	(0.50		)	(0.14		)	(0.94		)
Diluted net loss earnings per share (c)	(0.24		)	(0.07		)	(0.50		)	(0.14		)	(0.94		)
Basic and diluted weighted average shares outstanding	12,534			12,862			13,258			16,337			13,748

_______________


(a)	The third quarter of fiscal 2013 includes a loss of $4,101,000 associated with the settlement of the earn-out consideration to Interpoint (Note 6).


(b)	During the third quarter of fiscal 2013, the Company recorded an immaterial correction of an error regarding a $188,145 fiscal second quarter 2013 understatement of deemed dividends on its Series A Preferred Stock, with an offsetting understatement of additional paid-in capital.


(c)	Quarterly amounts may not be additive.


(d)	The fourth quarter of fiscal 2014 includes a $1,952,000 loss associated with the impairment of Meta trade name.

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References+ Details

Private Placement Investment

12 Months Ended

Jan. 31, 2015

Equity [Abstract]

PRIVATE PLACEMENT INVESTMENT

On August 16, 2012, the Company completed a $12,000,000 private placement investment (“private placement investment”) with affiliated funds and accounts of Great Point Partners, LLC, and Noro-Moseley Partners VI, L.P., and another investor. The investment consisted of the following instruments: issuance of 2,416,785 shares of a new Series A 0% Redeemable Convertible Preferred Stock (“Series A Preferred Stock”) at $3.00 per share, common stock warrants (“warrants”) exercisable for up to 1,200,000 shares of the Company's common stock at an exercise price of $3.99 per share, and convertible subordinated notes payable in the aggregate principal amount of $5,699,577, which upon shareholder approval, convert into up to 1,583,210 shares of Series A Preferred Stock. The proceeds were allocated among the instruments based on their relative fair values as follows:



	Adjusted Fair Value at August 16, 2012		Proceeds Allocation at August 16, 2012
Instruments:
Series A Preferred Stock	$	9,907,820	$	6,546,146	(1)
Convertible subordinated notes payable	5,699,577		3,765,738		(2)
Warrants	2,856,000		1,688,116		(3)
Total investment	$	18,463,397	$	12,000,000

_______________

(1)

The Series A Preferred Stock convert on a 1:1 basis into common stock, but differ in value from common stock due to the downside protection relative to common stock in the event the Company liquidates, and the downside protection, if, after four years, the holder has not converted and the stock is below $3.00. The fair value of Series A Preferred Stock was determined using a Monte-Carlo simulation following a Geometric Brownian Motion, using the following assumptions: annual volatility of 75%, risk-free rate of 0.9% and dividend yield of 0.0%. The model also utilized the following assumptions to account for the conditions within the agreement: after four years, if the simulated common stock price fell below a price of $3.00 per share, the convertible preferred stock would automatically convert to common stock on a 1:1 basis moving forward at a price of exactly $3.00 per share and a forced conversion if the simulated stock price exceeded $8.00 per share.

(2)

The fair value of convertible subordinated notes payable was determined based on its current yield as compared to that of those currently outstanding in the marketplace. Management reviewed the convertible note agreement and determined that the note's interest rate is a reasonable representative of a market rate; therefore the face or principal amount of the loan is a reasonable estimate of its fair value.

(3)

The fair value of the common stock warrants was determined using a Monte-Carlo simulation following a Geometric Brownian motion, using the following assumptions: annual volatility of 75%, risk-free rate of 0.9%, dividend yield of 0.0% and expected life of 5 years. Because the dilutive down-round financing was subject to approval by shareholder vote which had not happened at the time of the valuation, the model utilized the assumption that the down-round financing would not occur within the simulation.

The Company incurred legal, placement and other adviser fees of $1,894,000, including $754,000 in costs for warrants issued to placement agents. The total transaction costs were allocated among the instruments of the private placement investment based on their relative fair values as follows: $611,000 to subordinated convertible notes as deferred financing costs, $1,020,000 to Series A Preferred Stock as discount on Series A Preferred Stock and $263,000 to warrants as a charge to additional paid in capital.

Series A Convertible Preferred Stock

In connection with the private placement investment, the Company issued 2,416,785 shares of Series A Preferred Stock at $3.00 per share. Each share of the Series A Preferred Stock is convertible into one share of the Company's common stock. The price per share of Series A Preferred Stock and the conversion price for the common stock was less than the “market value” of the common stock of $3.82 (as defined in the rules of the Nasdaq Stock Market) on the date of execution of the definitive agreements. The Series A Preferred Stock does not pay a dividend, however, the holders are entitled to receive dividends on shares of Preferred Stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock. The Series A Preferred Stock have voting rights on a modified as-if-converted-to-common-stock-basis. The Series A Preferred Stock has a non-participating liquidation right equal to the original issue price plus accrued unpaid dividends, which are senior to the Company’s common stock. The Series A Preferred Stock can be converted to common shares at any time by the holders, or at the option of the Company if the arithmetic average of the daily volume weighted average price of the common stock for the ten day period prior to the measurement date is greater than $8.00 per share, and the average daily trading volume for the sixty day period immediately prior to the measurement date exceeds 100,000 shares. The conversion price is $3.00 per share, subject to certain adjustments.

The allocation of the proceeds and transaction costs based on relative fair values of the instruments resulted in recognition of a discount on the Series A Preferred Stock of $4,410,000, including discount from beneficial conversion feature of $2,686,000, which is being amortized from the date of issuance to the earliest redemption date. For the year ended January 31, 2015, 2014 and 2013, the Company recognized $1,038,000, $1,181,000 and $176,000, respectively, of amortization of the discount on Series A Preferred Stock as deemed dividends charged to additional paid in capital, computed under the effective interest rate method. The value of the beneficial conversion feature is calculated as the difference between the effective conversion price of the Series A Preferred Stock and the fair market value of the common stock into which the Series A Preferred Stock are convertible at the commitment date.

On November 1, 2012, upon shareholder approval, the convertible subordinated notes were converted into shares of Series A Convertible Preferred Stock. The convertible subordinated notes had an aggregate principal amount of $5,699,577 and converted into an aggregate of 1,583,210 shares of Preferred Stock. The Company recorded a loss upon conversion of $5,913,000 which represented the difference between the aggregate fair value of the Preferred Stock issued of $9,183,000, based on a $5.80 fair value per share, and the total of carrying value of the notes and unamortized deferred financing cost of $3,270,000. The shares of Series A Preferred Stock issued for the conversion of notes payable are recorded at their aggregate redemption value of $4,750,000 with the difference between the fair value and redemption value of $4,433,000 recorded as additional paid in capital. The fair value of the Preferred Stock was determined using a Monte-Carlo simulation based on the following assumptions: annual volatility of 75%, risk-free rate of 0.8%, and dividend yield of 0.0%. The model also utilized the following assumptions to account for the conditions within the agreement: after four years, if the simulated common stock price fell below a price of $3.00 per share, the convertible preferred stock would automatically convert to common stock on a 1:1 basis moving forward at a price of exactly $3.00 per share and a forced conversion if the simulated stock price exceeded $8.00 per share.

During fiscal 2013, the Company determined there was an immaterial correction error in the proceeds allocation recorded in fiscal 2012. The Company has corrected these adjustments and they are reflected in the fiscal 2013 consolidated financial statements and this Note 15.

The following table sets forth the activity of the Series A Preferred Stock, classified as temporary equity, during the periods presented:



	Number of Shares		Series A Preferred Stock
Series A Preferred Stock, January 31, 2012	—		$	—
Issuance from private placement, at redemption value	2,416,785		7,250,355
Discount related to warrants (1)	—		(704,209		)
Discount related to beneficial conversion feature	—		(2,685,973		)
Discount related to issuance cost	—		(1,020,135		)
Issuance of shares at redemption value for conversion of notes payable	1,583,210		4,749,630
Accretion of Preferred Stock discount	—		176,048
Series A Preferred Stock, January 31, 2013	3,999,995		7,765,716
Conversion of Preferred Stock to Common Stock	(1,050,000	)	(3,150,000		)
Accretion of Preferred Stock discount	—		1,180,904
Valuation adjustment (Note 4)	—		(196,952		)
Series A Preferred Stock, January 31, 2014	2,949,995		5,599,668
Accretion of Preferred Stock discount	—		1,038,310
Series A Preferred Stock, January 31, 2015	2,949,995		$	6,637,978

______________

(1) The discount related to warrants represents the difference between the redemption value of the Series A Preferred Stock, issued in conjunction with the private placement, and its allocated proceeds.

At any time following August 31, 2016, each share of Series A Preferred Stock is redeemable at the option of the holder for an amount equal to the initial issuance price of $3.00 (adjusted to reflect stock splits, stock dividends or like events) plus any accrued and unpaid dividends thereon. The Series A Preferred Stock are classified as temporary equity as the securities are redeemable solely at the option of the holder.

In fiscal 2013, 1,050,000 shares of the Company's Series A Convertible Preferred Stock were converted into Common Stock. As a result, Series A Convertible Preferred Stock was reduced by $3,150,000, with the offsetting increase to Common Stock and Additional Paid-in Capital. As of January 31, 2015 and 2014, 2,949,995 shares of Series A Convertible Preferred Stock remained outstanding.

Common Stock Warrants

In conjunction with the private placement investment, the Company issued common stock warrants exercisable for up to 1,200,000 of the Company's common stock at an exercise price of $3.99 per share. The warrants can be exercised in whole or in part during the period beginning on February 17, 2013 until five years from such initial exercise date. The warrants also include a cashless exercise option which allows the holder to receive a number of shares of common stock based on an agreed upon formula in exchange for the warrant rather than paying cash to exercise. The proceeds, net of transaction costs, allocated to the warrants of $1,425,000 were classified as equity on August 16, 2012, the date of issuance.

Effective October 31, 2012, upon shareholder approval of anti-dilution provisions that reset the warrants’ exercise price if a dilutive issuance occurs, the warrants were reclassified as derivative liabilities. The provisions require the exercise price to reset to the lower price at which the dilutive issuance is consummated, if the dilutive issuance occurs prior to the second anniversary of the warrants’ issuance. If a dilutive issuance occurs after the second anniversary of the warrants’ issuance, then the exercise price will be reset in accordance with a weighted average formula that provides for a partial reset, based on the number of shares raised in the dilutive issuance relative to the number of common stock equivalents outstanding at the time of the dilutive issuance. The change in fair value of the warrants was accounted for as an adjustment to stockholders’ equity for the period between the date of the contract’s last classification as equity to the date of reclassification to liability. The fair value of the warrants was $4,139,000 at October 31, 2012. These warrants are accounted for as derivative liabilities effective October 31, 2012, and as such, are re-valued at each reporting date, which changes in fair value recognized in earnings each reporting period as a charge or credit to other expenses.

On October 19, 2012, the Company also issued 200,000 warrants to its placement agents as a portion of the fees for services rendered in the private placement investment. The warrants had an initial exercise date of May 1, 2013 and are exercisable for a five-year term thereafter at a stated exercise price of $4.06 per share and could be exercised in whole or in part at any time. The warrants also included a cashless exercise option which allowed the holder to receive a number of shares of common stock based on an agreed upon formula in exchange for the warrants rather than paying cash to exercise. The warrants have no reset provisions. The warrants had a grant date fair value of $754,000, and are classified as equity on the consolidated balance sheet. The estimated fair value of the warrants was determined by using Monte-Carlo simulations based on the following assumptions: annual volatility of 75%; risk-free rate of 0.9%, dividend yield of 0.0% and expected life of five years. The following table sets forth the warrants issued and outstanding as of January 31, 2015:



	Number of Shares Issuable	Weighted Average Exercise Price
Warrants - private placement	1,200,000	$	3.99
Warrants - placement agent	200,000	4.06
Total	1,400,000	$	4.00

The fair value of the private placement warrants was $1,834,000 and $4,117,000 at January 31, 2015 and 2014, respectively. No warrants were exercised or canceled during fiscal 2014, 2013 and 2012.

Convertible Subordinated Notes

Please refer to Note 6 - Debt.

STOCKHOLDERS' EQUITY

On November 27, 2013, the Company closed its public offering of 3,450,000 shares of the Company’s common stock, including 450,000 shares issued in connection with an overallotment option exercised by the underwriters, at a price to the public of $6.50 per share. Aggregate net proceeds from the offering were $20,493,000 after deducting $1,680,000 in underwriting discounts and commissions, and offering expenses incurred by the Company of $158,000.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Stockholders' Equity

12 Months Ended

Jan. 31, 2015

Equity [Abstract]

STOCKHOLDERS' EQUITY

PRIVATE PLACEMENT INVESTMENT



	Adjusted Fair Value at August 16, 2012		Proceeds Allocation at August 16, 2012
Instruments:
Series A Preferred Stock	$	9,907,820	$	6,546,146	(1)
Convertible subordinated notes payable	5,699,577		3,765,738		(2)
Warrants	2,856,000		1,688,116		(3)
Total investment	$	18,463,397	$	12,000,000

_______________

(1)

(2)

(3)

Series A Convertible Preferred Stock

The following table sets forth the activity of the Series A Preferred Stock, classified as temporary equity, during the periods presented:



	Number of Shares		Series A Preferred Stock
Series A Preferred Stock, January 31, 2012	—		$	—
Issuance from private placement, at redemption value	2,416,785		7,250,355
Discount related to warrants (1)	—		(704,209		)
Discount related to beneficial conversion feature	—		(2,685,973		)
Discount related to issuance cost	—		(1,020,135		)
Issuance of shares at redemption value for conversion of notes payable	1,583,210		4,749,630
Accretion of Preferred Stock discount	—		176,048
Series A Preferred Stock, January 31, 2013	3,999,995		7,765,716
Conversion of Preferred Stock to Common Stock	(1,050,000	)	(3,150,000		)
Accretion of Preferred Stock discount	—		1,180,904
Valuation adjustment (Note 4)	—		(196,952		)
Series A Preferred Stock, January 31, 2014	2,949,995		5,599,668
Accretion of Preferred Stock discount	—		1,038,310
Series A Preferred Stock, January 31, 2015	2,949,995		$	6,637,978

______________

Common Stock Warrants



	Number of Shares Issuable	Weighted Average Exercise Price
Warrants - private placement	1,200,000	$	3.99
Warrants - placement agent	200,000	4.06
Total	1,400,000	$	4.00

The fair value of the private placement warrants was $1,834,000 and $4,117,000 at January 31, 2015 and 2014, respectively. No warrants were exercised or canceled during fiscal 2014, 2013 and 2012.

Convertible Subordinated Notes

Please refer to Note 6 - Debt.

STOCKHOLDERS' EQUITY

- Definition

+ References

+ Details

Subsequent Events	12 Months Ended
Subsequent Events	Jan. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS We have evaluated subsequent events through April 16, 2015 and have determined that there are no subsequent events after January 31, 2015 for which disclosure is required, other than the matter described in Note 13 - Commitments and Contingencies - Litigation, the debt covenant waiver as discussed in Note 6 - Debt, and the following. On April 15, 2015, the Company entered into a sales order with Nant Health, LLC whereby the Company would license its Scheduling solution to Nant Health for the use of Nant Health’s customers. The sales order was under a previously entered License and Services Agreement between Nant Health and the Company. Robert E. Watson, the President and Chief Executive Officer of Nant Health, is a member of the Company’s Board of Directors.

Valuation and Qualifying Accounts and Reserves

12 Months Ended

Jan. 31, 2015

Valuation and Qualifying Accounts [Abstract]

Schedule II, Valuation and Qualifying Accounts and Reserves

Schedule II

Valuation and Qualifying Accounts and Reserves

Streamline Health Solutions, Inc.

For the three years ended January 31, 2015



			Additions
Description	Balance at Beginning of Period		Charged to Costs and Expenses		Charged to Other Accounts		Deductions			Balance at End of Period
	(in thousands)
Year ended January 31, 2015:
Allowance for doubtful accounts	$	267	$	441	$	1	$	(43	)	$	666
Year ended January 31, 2014:
Allowance for doubtful accounts	$	134	$	331	$	—	$	(198	)	$	267
Year ended January 31, 2013:
Allowance for doubtful accounts	$	100	$	67	$	34	$	(67	)	$	134



			Changes through
Description	Balance at Beginning of Period		Tax Expense			Other Comprehensive Income			Goodwill		Balance at End of Period
	(in thousands)
Year ended January 31, 2015:
Valuation allowance on deferred tax assets	$	7,667	$	4,031		$	(41	)	$	897	$	12,554
Year ended January 31, 2014:
Valuation allowance on deferred tax assets	$	7,835	$	(209	)	$	41		$	—	$	7,667
Year ended January 31, 2013:
Valuation allowance on deferred tax assets	$	9,835	$	(2,000	)	$	—		$	—	$	7,835

Significant Accounting Policies (Policies)

12 Months Ended

Jan. 31, 2015

Accounting Policies [Abstract]

Basis of Presentation

Use of Estimates

Cash and Cash Equivalents

Receivables and Allowance for Doubtful Accounts

Receivables

Allowance for Doubtful Accounts

Property and Equipment

Property and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related assets. Estimated useful lives are as follows:



Computer equipment and software	3-4 years
Office equipment	5 years
Office furniture and fixtures	7 years
Leasehold improvements	Term of lease

Depreciation expense for property and equipment in fiscal 2014, 2013 and 2012 was $1,005,000, $718,000 and $726,000, respectively.

Leases

Debt Issuance Costs

Interest Rate Swap

During the third quarter of fiscal 2014, the interest rate swap was terminated prior to its maturity, and losses accumulated in other comprehensive loss were reclassified into earnings.

Impairment of Long-Lived Assets

Capitalized Software Development Costs

Fair Value of Financial Instruments

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Revenue Recognition


•	Persuasive evidence of an arrangement exists,


•	Delivery has occurred or services have been rendered,


•	The arrangement fees are fixed or determinable, and


•	Collection is considered probable.

Revenues from resellers are recognized gross of royalty payments to resellers.

Multiple Element Arrangements


•	Provide updated guidance on how deliverables of an arrangement are separated, and how consideration is allocated;


•	Eliminate the residual method and require entities to allocate revenue using the relative selling price method and;


•	Require entities to allocate revenue to an arrangement using the estimated selling price (“ESP”) of deliverables if it does not have vendor specific objective evidence (“VSOE”) or third party evidence (“TPE”) of selling price.

Terms used in evaluation are as follows:


•	VSOE — the price at which an element is sold as a separate stand-alone transaction


•	TPE — the price of an element, charged by another company that is largely interchangeable in any particular transaction


•	ESP — the Company’s best estimate of the selling price of an element of the transaction

Software as a Service

System Sales

Maintenance and Support Services

Term Licenses

Professional Services

Concentrations

Business Combinations

Goodwill and Intangible Assets


•	significant under performance relative to historical or projected future operating results;


•	significant changes in the manner of use of the acquired assets or the strategy for the overall business;


•	identification of other impaired assets within a reporting unit;


•	disposition of a significant portion of an operating segment;


•	significant negative industry or economic trends;


•	significant decline in the Company's stock price for a sustained period; and


•	a decline in the market capitalization relative to the net book value.

Determining whether a triggering event has occurred involves significant judgment by the Company.

The Company determined that it has one operating segment and one reporting unit.

Equity Awards

Income Taxes

Net Loss Per Common Share

Loss Contingencies

Recent Accounting Pronouncements

Significant Accounting Policies (Tables)

12 Months Ended

Jan. 31, 2015

Accounting Policies [Abstract]

Schedule of Bad Debt Expense

Bad debt expense for fiscal years 2014, 2013 and 2012 are as follows:



	2014		2013		2012
Bad debt expense	$	440,771	$	330,907	$	67,464

Property, Plant and Equipment

Property and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related assets. Estimated useful lives are as follows:



Computer equipment and software	3-4 years
Office equipment	5 years
Office furniture and fixtures	7 years
Leasehold improvements	Term of lease

Schedule of Capitalized Software Development Costs



	Fiscal Year
Amortization expense on internally developed software included in:	2014		2013		2012
Cost of systems sales	$	3,352,000	$	2,769,000	$	2,435,000
Cost of software as a service	326,000		423,000		224,000
Total amortization expense on internally developed software	$	3,678,000	$	3,192,000	$	2,659,000

Schedule of Earnings Per Share, Basic and Diluted

The following is the calculation of the basic and diluted net loss per share of common stock:



				Fiscal Year
	2014			2013			2012
Net loss	$	(12,011,457	)	$	(11,717,190	)	$	(5,378,729	)
Less: deemed dividends on Series A Preferred Stock	(1,038,310		)	(1,180,904		)	(176,048		)
Net loss attributable to common shareholders	$	(13,049,767	)	$	(12,898,094	)	$	(5,554,777	)
Weighted average shares outstanding used in basic per common share computations	18,261,800			13,747,700			11,634,540
Stock options and restricted stock	—			—			—
Number of average shares used in diluted per common share computation	18,261,800			13,747,700			11,634,540
Basic net loss per share of common stock	$	(0.71	)	$	(0.94	)	$	(0.48	)
Diluted net loss per share of common stock	$	(0.71	)	$	(0.94	)	$	(0.48	)

Acquisitions (Tables)

12 Months Ended

Jan. 31, 2015

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimate fair values as of the acquisition date as follows:



	Balance at October 25, 2013
Assets purchased:
License agreement	$	4,431,000
Existing customer relationship	408,000
Covenant not to compete	129,000
Working capital	124,000
Other assets	25,000
Goodwill (1)	108,000
Total assets purchased	$	5,225,000
Consideration:
Cash paid	$	3,000,000
Future royalty commitment	2,225,000
Total consideration	$	5,225,000

_______________


(1)	Goodwill represents the excess of purchase price over the estimated fair value of net tangible and intangible assets acquired, which is not deductible for tax purposes.

Under the acquisition method of accounting, the purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date as follows:



	Balance at August 16, 2012
Assets purchased:
Cash	$	1,126,000
Accounts receivable	2,300,000
Property and equipment	133,000
Other assets	513,000
Client relationships	4,464,000
Internally-developed software	3,646,000
Trade name (2)	1,588,000
Supplier agreements	1,582,000
Covenants not to compete	720,000
Goodwill (1), (2)	8,073,000
Total assets purchased	$	24,145,000
Liabilities assumed:
Accounts payable and accrued liabilities	1,259,000
Deferred revenue obligation, net	3,494,000
Deferred tax liabilities	4,602,000
Net assets acquired	$	14,790,000
Consideration:
Company common stock	$	1,502,000
Cash paid	13,288,000
Total consideration	$	14,790,000

_______________


(1)	Goodwill represents the excess of purchase price over the estimated fair value of net tangible and intangible assets acquired, which is not deductible for tax purposes.


(2)	See Note 7 - Goodwill and Intangible Assets for further changes in fiscal 2013. In fiscal 2014, Meta trade name was deemed impaired and its corresponding balance was fully written off.

The preliminary purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date as follows:



	Balance at February 3, 2014
Assets purchased:
Cash	$	59,000
Accounts receivable (2)	221,000
Other assets	61,000
Internally-developed software	2,017,000
Client relationships	647,000
Trade name	26,000
Goodwill (1)	4,251,000
Total assets purchased	7,282,000
Liabilities assumed:
Accounts payable and accrued liabilities	362,000
Deferred revenue obligation, net	793,000
Deferred income taxes	9,000
Net assets acquired	$	6,118,000
Cash paid	$	6,118,000

_______________


(1)	Goodwill represents the excess of purchase price over the estimated fair value of net tangible and intangible assets acquired, which is not deductible for tax purposes.


(2)	During the fourth quarter of fiscal 2014, the Company recorded an immaterial correction of an error to reduce the accounts receivable acquired from Unibased by $266,000, with the offset to goodwill.

Debt (Tables)

12 Months Ended

Jan. 31, 2015

Debt Disclosure [Abstract]

Schedule of Minimum EBITDA Levels

The following table shows our future minimum EBITDA covenant thresholds, as modified by the amendment to the Credit Agreement:



For the four-quarter period ending	Minimum EBITDA
April 30, 2015	$	(2,500,000	)
July 31, 2015	(1,750,000		)
October 31, 2015	(750,000		)
January 31, 2016	500,000

Summary of Term Loan and Line of Credit

Outstanding principal balances on debt consisted of the following at:



	January 31, 2015		January 31, 2014
Senior term loan (1)	$	10,000,000	$	8,298,000
Note payable	—		900,000
Capital lease	1,365,000		227,000
Total	11,365,000		9,425,000
Less: Current portion	1,282,000		1,620,000
Non-current portion of long-term debt	$	10,083,000	$	7,805,000

_______________


(1)	January 31, 2014 balance represents total principal due, therefore it is not reduced by the debt discount of $112,000. In the consolidated balance sheets, the term loan is presented net of this discount.

Schedule of Future Principal Repayments of Long-Term Debt

Future repayments of long-term debt by fiscal year consisted of the following at January 31, 2015:



	Senior Term Loan		Capital Lease (1)		Total
2015	$	500,000	$	858,000	$	1,358,000
2016	750,000		457,000		1,207,000
2017	1,000,000		93,000		1,093,000
2018	1,000,000		—		1,000,000
2019	6,750,000		—		6,750,000
Total repayments	$	10,000,000	$	1,408,000	$	11,408,000

_______________


(1)	Future minimum lease payments include principal plus interest.

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(e),(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

+ Details

Goodwill and Intangible Assets (Tables)

12 Months Ended

Jan. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill Activity

The goodwill activity is summarized as follows:



	Goodwill
Balance January 31, 2013	$	12,133,000
Goodwill acquired during the year	108,000
Adjustments to goodwill during the year	(307,000		)
Balance January 31, 2014	11,934,000
Goodwill acquired during the year	4,251,000
Balance January 31, 2015	$	16,185,000

Schedule of Goodwill and Intangibles Components

Intangible assets, net, consist of the following:



	January 31, 2015
	Estimated Useful Life	Gross Assets		Accumulated Amortization		Net Assets
Definite-lived assets:
Trade name	1 year	$	26,000	$	26,000	$	—
Client relationships	10-15 years	5,932,000		1,548,000		4,384,000
Covenants not to compete	0.5-15 years	856,000		606,000		250,000
Supplier agreements	5 years	1,582,000		778,000		804,000
License agreement	15 years	4,431,000		369,000		4,062,000
Total		$	12,827,000	$	3,327,000	$	9,500,000



	January 31, 2014
	Estimated Useful Life	Gross Assets		Accumulated Amortization		Net Assets
Indefinite-lived assets:
Trade name	N/A	$	1,952,000	$	—	$	1,952,000
Definite-lived assets:
Client relationships	10-15 years	$	5,285,000	$	862,000	$	4,423,000
Covenants not to compete	0.5-15 years	856,000		533,000		323,000
Supplier agreements	5 years	1,582,000		461,000		1,121,000
License agreement	15 years	4,431,000		74,000		4,357,000
Total		$	14,106,000	$	1,930,000	$	12,176,000

Amortization Schedule of Intangible Assets

Amortization over the next five fiscal years for intangible assets is estimated as follows:



	Annual Amortization Expense
2015	$	1,345,000
2016	1,298,000
2017	1,088,000
2018	863,000
2019	826,000
Thereafter	4,080,000
Total	$	9,500,000

Income Taxes (Tables)

12 Months Ended

Jan. 31, 2015

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Expense (Benefit)

Income taxes consist of the following:



			Fiscal Year
	2014		2013			2012
Current tax benefit (expense):
Federal	$	131,816	$	(8,705	)	$	(9,391	)
State	34,611		130,048			(37,594		)
	166,427		121,343			(46,985		)
Deferred tax benefit (expense):
Federal	663,681		26,491			2,642,580
State	56,901		(47,376		)	292,942
	720,582		(20,885		)	2,935,522
Current and deferred income tax benefit	$	887,009	$	100,458		$	2,888,537

Schedule of Effective Income Tax Rate Reconciliation

The income tax benefit for income taxes differs from the amount computed using the federal statutory income tax rate as follows:



				Fiscal Year
	2014			2013			2012
Federal tax benefit at statutory rate	$	4,385,479		$	4,018,000		$	2,810,870
State and local taxes, net of federal benefit	325,966			488,626			255,348
Change in valuation allowance	(4,030,864		)	(3,659,160		)	2,000,295
Permanent items:
Loss from conversion of notes payable	—			—			(1,937,411		)
Incentive stock options	(421,366		)	(343,117		)	—
Transaction costs	(5,291		)	(78,476		)	(339,320		)
Change in fair value of warrants liability	776,337			(159,249		)	166,408
Other	(44,719		)	(351,857		)	(45,540		)
Reserve for uncertain tax position	164,127			(11,642		)	—
Other	(262,660		)	197,333			(22,113		)
Income tax benefit	$	887,009		$	100,458		$	2,888,537

Schedule of Deferred Tax Assets and Liabilities

The income tax effects of these temporary differences and credits are as follows:



	January 31,
	2015			2014
Deferred tax assets:
Allowance for doubtful accounts	$	245,252		$	98,661
Deferred revenue	372,275			19,561
Accruals	174,658			351,827
Net operating loss carryforwards	14,905,174			7,763,718
Stock compensation expense	438,659			362,145
Property and equipment	—			147,691
AMT credit	102,144			102,144
Other	8,912			62,783
Total deferred tax assets	16,247,074			8,908,530
Valuation allowance	(12,554,242		)	(7,666,626		)
Net deferred tax assets	3,692,832			1,241,904
Deferred tax liabilities:
Property and Equipment	(21,755		)	—
Definite-lived intangible assets	(3,671,077		)	(1,241,904		)
Indefinite-lived intangibles	(9,575		)	(720,581		)
Total deferred tax liabilities	(3,702,407		)	(1,962,485		)
Net deferred tax liabilities	$	(9,575	)	$	(720,581	)

Summary of Income Tax Contingencies

A reconciliation of the beginning and ending amounts of gross unrecognized tax benefits (excluding interest and penalties) is as follows:



	2014			2013			2012
Beginning of fiscal year	$	121,000		$	122,000		$	—
Additions for tax positions of prior years	—			—			122,000
Reductions for tax positions of prior years	—			(1,000		)	—
Reductions attributable to lapse of statute of limitations	(121,000		)	—			—
End of fiscal year	$	—		$	121,000		$	122,000

- Definition

Tabular disclosure of tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of income tax contingencies, including: (1) the policy on classification of interest and penalties; (2) a tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the period; the total amount(s) of: (3) unrecognized tax benefits that, if recognized, would affect the effective tax rate, and (4) interest and penalties recognized in each of the income statement and balance sheet; (5) for positions for which it is reasonably possible that the total amounts unrecognized will significantly change within 12 months of the reporting date the: (i) nature of the uncertainty, (ii) nature of the event that could occur that would cause the change, and (iii) an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made; and (6) a description of tax years that remain subject to examination by major tax jurisdictions.

+ References+ Details

Stock Based Compensation (Tables)

12 Months Ended

Jan. 31, 2015

Share-based Compensation [Abstract]

Schedule of Stock Option Activity

A summary of stock option activity is summarized as follows:



	Fiscal Year
	2014
	Options			Weighted Average Exercise Price
Outstanding — beginning of year	2,304,407			4.46
Granted	1,318,078			4.95
Exercised	(246,155		)	1.91
Expired	(168,060		)	5.31
Forfeited	(770,947		)	5.75
Outstanding — end of year	2,437,323			4.52
Exercisable — end of year	1,192,220			3.83
Aggregate intrinsic value of outstanding options at year end	$	9,798,038
Aggregate intrinsic value of exercisable options at year end	$	4,792,724

Schedule of Weighted-Average Assumptions



	2014		2013		2012
Expected life	6 years		6 years		5 years
Risk-free interest rate	1.35	%	1.81	%	0.35	%
Weighted average volatility factor	0.60		0.66		0.57
Dividend yield	—		—		—
Forfeiture rate	22	%	21	%	—



	Number of Options	Average Exercise Price			Remaining Life in Years
January 31, 2015
Outstanding	2,437,323	$	4.52	(1)	7.91
Exercisable	1,192,220	$	3.83	(2)	6.67

_______________


(1)	The exercise prices range from $1.65 to $8.17, of which 463,924 shares are between $1.65 and $2.00 per share, 519,978 shares are between $2.08 and $4.00 per share, and 1,453,421 shares are between $4.08 and $8.17 per share.


(2)	The exercise prices range from $1.65 to $8.17, of which 454,424 shares are between $1.65 and $2.00 per share, 280,667 shares are between $2.08 and $4.00 per share, and 457,129 shares are between $4.08 and $8.17 per share.

Schedule of Restricted Stock Award Activity

A summary of restricted stock award activity for the period is presented below:



	Non-vested Number of Shares		Weighted Average Grant Date Fair Value
Non-vested balance at January 31, 2012	126,457		$	1.68
Granted	137,325		2.01
Vested	(126,457	)	1.79
Forfeited/expired	—		—
Non-vested balance at January 31, 2013	137,325		$	2.01
Granted	29,698		6.65
Vested	(137,325	)	2.01
Forfeited/expired	—		—
Non-vested balance at January 31, 2014	29,698		$	6.01
Granted	120,306		4.31
Vested	(29,698	)	6.65
Forfeited/expired	—		—
Non-vested balance at January 31, 2015	120,306		$	4.31

Quarterly Results of Operations (Tables)

12 Months Ended

Jan. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

Selected Financial Information



Fiscal 2014 (In thousands, except per share data):	First Quarter			Second Quarter			Third Quarter			Fourth Quarter			2014
Revenues	$	6,951		$	7,242		$	6,837		$	6,595		$	27,625
Gross profit	3,398			4,221			3,793			3,209			14,621
Operating loss (d)	(3,593		)	(2,059		)	(2,713		)	(4,948		)	(13,312		)
Net loss	(2,671		)	(2,275		)	(2,256		)	(4,810		)	(12,011		)
Less: deemed dividends on Series A Preferred Shares	(230		)	(253		)	(269		)	(286		)	(1,038		)
Net loss attributable to common shareholders	(2,901		)	(2,528		)	(2,525		)	(5,096		)	(13,050		)
Basic net loss per share (c)	(0.16		)	(0.14		)	(0.14		)	(0.28		)	(0.71		)
Diluted net loss earnings per share (c)	(0.16		)	(0.14		)	(0.14		)	(0.28		)	(0.71		)
Basic and diluted weighted average shares outstanding	18,146			18,174			18,301			18,417			18,262

Fiscal 2013 (In thousands, except per share data):	First Quarter			Second Quarter			Third Quarter			Fourth Quarter			2013
Revenues	$	6,473		$	8,773		$	6,732		$	6,517		$	28,495
Gross profit	3,297			5,536			3,597			2,887			15,317
Operating profit (loss)	(1,373		)	997			(1,140		)	(4,802		)	(6,318		)
Net loss (a)	(2,710		)	(828		)	(6,232		)	(1,947		)	(11,717		)
Less: deemed dividends on Series A Preferred Shares (b)	(342		)	(16		)	(374		)	(449		)	(1,181		)
Net loss attributable to common shareholders	(3,051		)	(844		)	(6,607		)	(2,396		)	(12,898		)
Basic net loss per share (c)	(0.24		)	(0.07		)	(0.50		)	(0.14		)	(0.94		)
Diluted net loss earnings per share (c)	(0.24		)	(0.07		)	(0.50		)	(0.14		)	(0.94		)
Basic and diluted weighted average shares outstanding	12,534			12,862			13,258			16,337			13,748

_______________


(a)	The third quarter of fiscal 2013 includes a loss of $4,101,000 associated with the settlement of the earn-out consideration to Interpoint (Note 6).


(b)	During the third quarter of fiscal 2013, the Company recorded an immaterial correction of an error regarding a $188,145 fiscal second quarter 2013 understatement of deemed dividends on its Series A Preferred Stock, with an offsetting understatement of additional paid-in capital.


(c)	Quarterly amounts may not be additive.


(d)	The fourth quarter of fiscal 2014 includes a $1,952,000 loss associated with the impairment of Meta trade name.

Private Placement Investment (Tables)

12 Months Ended

Jan. 31, 2015

Equity [Abstract]

Schedule of Investment Allocation

The proceeds were allocated among the instruments based on their relative fair values as follows:



	Adjusted Fair Value at August 16, 2012		Proceeds Allocation at August 16, 2012
Instruments:
Series A Preferred Stock	$	9,907,820	$	6,546,146	(1)
Convertible subordinated notes payable	5,699,577		3,765,738		(2)
Warrants	2,856,000		1,688,116		(3)
Total investment	$	18,463,397	$	12,000,000

_______________

(1)

(2)

(3)

Series A Preferred Stock Activity

The following table sets forth the activity of the Series A Preferred Stock, classified as temporary equity, during the periods presented:



	Number of Shares		Series A Preferred Stock
Series A Preferred Stock, January 31, 2012	—		$	—
Issuance from private placement, at redemption value	2,416,785		7,250,355
Discount related to warrants (1)	—		(704,209		)
Discount related to beneficial conversion feature	—		(2,685,973		)
Discount related to issuance cost	—		(1,020,135		)
Issuance of shares at redemption value for conversion of notes payable	1,583,210		4,749,630
Accretion of Preferred Stock discount	—		176,048
Series A Preferred Stock, January 31, 2013	3,999,995		7,765,716
Conversion of Preferred Stock to Common Stock	(1,050,000	)	(3,150,000		)
Accretion of Preferred Stock discount	—		1,180,904
Valuation adjustment (Note 4)	—		(196,952		)
Series A Preferred Stock, January 31, 2014	2,949,995		5,599,668
Accretion of Preferred Stock discount	—		1,038,310
Series A Preferred Stock, January 31, 2015	2,949,995		$	6,637,978

______________

Schedule of Warrants Issued and Outstanding

The following table sets forth the warrants issued and outstanding as of January 31, 2015:



	Number of Shares Issuable	Weighted Average Exercise Price
Warrants - private placement	1,200,000	$	3.99
Warrants - placement agent	200,000	4.06
Total	1,400,000	$	4.00

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References+ Details

- Definition

Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References+ Details

Significant Accounting Policies - Additional Information (Details) (USD $)	12 Months Ended														12 Months Ended		0 Months Ended		3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2015 Convertible Preferred Stock	Jan. 31, 2014 Convertible Preferred Stock	Jan. 31, 2013 Convertible Preferred Stock	Jan. 31, 2015 Restricted Stock	Jan. 31, 2014 Restricted Stock	Jan. 31, 2013 Restricted Stock	Jan. 31, 2015 Warrant	Jan. 31, 2014 Warrant	Jan. 31, 2013 Warrant	Jan. 31, 2015 Employee Severance	Jan. 31, 2014 Employee Severance	Jan. 31, 2015 Minimum	Jan. 31, 2015 Maximum	Dec. 13, 2013 Interpoint Partners, LLC sqft	Apr. 10, 2012 Interpoint Partners, LLC sqft	Oct. 31, 2014 Meta sqft	Aug. 16, 2012 Meta sqft	Jan. 31, 2015 Assets Held under Capital Leases	Jan. 31, 2014 Assets Held under Capital Leases	Jan. 31, 2015 Stock Options	Jan. 31, 2014 Stock Options	Jan. 31, 2013 Stock Options	Aug. 16, 2012 Internally-developed software Meta	Jan. 31, 2015 Internally-developed software Unibased	Feb. 03, 2014 Internally-developed software Unibased
Allowance for Doubtful Accounts
Allowance for doubtful accounts	$ 665,962	$ 267,264
Concessions Accrual
Concessions Costs	58,000	58,000
Bad debt expense	440,771	330,907	67,464
Leases
Area under Lease																	24,335	8,582	10,350	10,000
Lease duration																	102 months	72 months	2 months
Duration of rent allowance																	8 months	4 months	63 months
Property and equipment, net	3,136,815	919,044																			1,515,000	261,000
Capitalized Software Development Costs
Capitalized computer software, additions	620,000	614,000	2,000,000
Intangible assets																										3,646,000	2,017,000	2,017,000
Useful life of capitalized computer software	5 years
Capitalized computer software, amortization	(3,677,991)	(3,192,157)	(2,659,365)
Research and development expense	9,756,206	7,088,077	2,948,313
Revenue Recognition
Deferred professional costs	570,000	331,000
Accumulated amortization, deferred finance costs	275,000	110,000
Accumulated depreciation and amortization	1,617,423	6,676,824																			494,000	76,000
Amortization of professional expenses	166,000	110,000	35,000
Goodwill and Intangible Assets
Estimated Useful Life															1 year	15 years
Severances
Severance expenses	666,000	384,000	866,000
Accrued severances													159,000	0
Equity Awards
Share-based compensation expense	1,934,298	1,660,598	956,144
Comprehensive Loss
Other comprehensive income (loss)	111,086	(111,086)	0
Income Taxes
Reserves for uncertain tax positions and corresponding interest and penalties	$ 0	$ 181,000
Net Earnings (Loss) Per Common Share
Antidilutive securities				2,949,995	2,949,995	3,999,995	120,306	29,698	137,325	1,400,000	1,400,000	1,400,000
Options outstanding	2,437,323																						2,437,323	2,304,407	2,685,237

Significant Accounting Policies - Property, Plant, and Equipment (Details) (USD $)	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Property, Plant and Equipment
Depreciation	$ 1,005,283	$ 718,097	$ 726,406
Computer Equipment and Software \| Minimum
Property, Plant and Equipment
Property, plant and equipment, useful life	3 years
Computer Equipment and Software \| Maximum
Property, Plant and Equipment
Property, plant and equipment, useful life	4 years
Office Equipment
Property, Plant and Equipment
Property, plant and equipment, useful life	5 years
Furniture and Fixtures
Property, Plant and Equipment
Property, plant and equipment, useful life	7 years

Significant Accounting Policies - Capitalized Software Development Costs (Details) (USD $)	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Accounting Policies [Abstract]
Cost of systems sales	$ 3,352,000	$ 2,769,000	$ 2,435,000
Cost of software as a service	326,000	423,000	224,000
Total amortization expense on internally developed software	$ 3,677,991	$ 3,192,157	$ 2,659,365

Significant Accounting Policies - Earnings Per Share (Details) (USD $)	3 Months Ended								12 Months Ended
	Jan. 31, 2015	Oct. 31, 2014	Jul. 31, 2014	Apr. 30, 2014	Jan. 31, 2014	Oct. 31, 2013	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Accounting Policies [Abstract]
Net loss	$ (4,810,000)	$ (2,256,000)	$ (2,275,000)	$ (2,671,000)	$ (1,947,000)	$ (6,232,000)	$ (828,000)	$ (2,710,000)	$ (12,011,457)	$ (11,717,190)	$ (5,378,729)
Less: deemed dividends on Series A Preferred Shares	(286,000)	(269,000)	(253,000)	(230,000)	(449,000)	(374,000)	(16,000)	(342,000)	(1,038,310)	(1,180,904)	(176,048)
Net loss attributable to common shareholders	$ (5,096,000)	$ (2,525,000)	$ (2,528,000)	$ (2,901,000)	$ (2,396,000)	$ (6,607,000)	$ (844,000)	$ (3,051,000)	$ (13,049,767)	$ (12,898,094)	$ (5,554,777)
Basic and diluted weighted average shares outstanding (shares)	18,417,000	18,301,000	18,174,000	18,146,000	16,337,000	13,258,000	12,862,000	12,534,000	18,261,800	13,747,700	11,634,540
Stock options and restricted stock									0	0	0
Number of average shares used in diluted per common share computation									18,261,800	13,747,700	11,634,540
Basic net loss per common share (in dollars per share)	$ (0.28)	$ (0.14)	$ (0.14)	$ (0.16)	$ (0.14)	$ (0.50)	$ (0.07)	$ (0.24)	$ (0.71)	$ (0.94)	$ (0.48)
Diluted net loss per common share (in dollars per share)	$ (0.28)	$ (0.14)	$ (0.14)	$ (0.16)	$ (0.14)	$ (0.50)	$ (0.07)	$ (0.24)	$ (0.71)	$ (0.94)	$ (0.48)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

Acquisitions Narrative (Details) (USD $)	3 Months Ended								12 Months Ended			0 Months Ended	12 Months Ended			0 Months Ended		12 Months Ended	0 Months Ended
Acquisitions Narrative (Details) (USD $)	Jan. 31, 2015	Oct. 31, 2014	Jul. 31, 2014	Apr. 30, 2014	Jan. 31, 2014	Oct. 31, 2013	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013	Aug. 16, 2012 Meta	Jan. 31, 2013 Meta	Jan. 31, 2014 Meta	Oct. 31, 2012 Meta	Oct. 25, 2013 Montefiore Medical Center	Feb. 03, 2014 Unibased	Jan. 31, 2015 Unibased	May 06, 2014 CentraMed Inc
Business Acquisition [Line Items]
Effective Date of Acquisition												Aug. 16, 2012
Total purchase price												$ 14,790,000				$ 5,225,000	$ 6,500,000
Cash payment									6,058,225	3,000,000	12,161,614	13,288,000				3,000,000	6,118,000		4,800,000
Issuance of common shares												393,086
Price Per Share												$ 4.07
Fair value of common stock												$ 3.82
Acquisition Related Costs													1,306,000
Percentage of Voting Interests Acquired															100.00%
Indemnification Provisions														394,000
Deferred Tax Benefit													3,000,000
Cash paid									6,058,225	3,000,000	12,161,614	13,288,000				3,000,000	6,118,000		4,800,000
On going Royalty Payments																3,000,000
Revenues																		1,849,000
Net loss	$ 4,810,000	$ 2,256,000	$ 2,275,000	$ 2,671,000	$ 1,947,000	$ 6,232,000	$ 828,000	$ 2,710,000	$ 12,011,457	$ 11,717,190	$ 5,378,729							$ 414,000

Acquisitions (Assets Acquired and Liabilities Assumed) (Details) (USD $)	3 Months Ended	12 Months Ended			0 Months Ended			3 Months Ended
	Oct. 31, 2013	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013	Oct. 25, 2013 Montefiore Medical Center	Aug. 16, 2012 Meta	Feb. 03, 2014 Unibased	Jan. 31, 2015 Unibased	Feb. 03, 2014 Unibased	Oct. 25, 2013 License agreement Montefiore Medical Center	Oct. 25, 2013 Client relationships Montefiore Medical Center	Aug. 16, 2012 Client relationships Meta	Feb. 03, 2014 Client relationships Unibased	Aug. 16, 2012 Internally-developed software Meta	Jan. 31, 2015 Internally-developed software Unibased	Feb. 03, 2014 Internally-developed software Unibased	Aug. 16, 2012 Trade name Meta	Feb. 03, 2014 Trade name Unibased	Aug. 16, 2012 Supplier agreements Meta	Oct. 25, 2013 Covenants not to compete Montefiore Medical Center	Aug. 16, 2012 Covenants not to compete Meta
Business Acquisition [Line Items]
Cash						$ 1,126,000			$ 59,000
Accounts receivable						2,300,000			221,000
Property and equipment						133,000
Other assets						513,000			61,000
Intangible assets										4,431,000	408,000	4,464,000	647,000	3,646,000	2,017,000	2,017,000	1,588,000	26,000	1,582,000	129,000	720,000
Working capital					124,000
Other assets					25,000
Goodwill		16,184,667	11,933,683	12,133,000	108,000	8,073,000			4,251,000
Total assets purchased					5,225,000	24,145,000			7,282,000
Accounts payable and accrued liabilities						1,259,000			362,000
Deferred revenue obligation, net						3,494,000			793,000
Deferred tax liabilities						4,602,000			9,000
Net assets acquired						14,790,000			6,118,000
Company common stock						1,502,000
Cash paid		6,058,225	3,000,000	12,161,614	3,000,000	13,288,000	6,118,000
Future royalty commitment					2,225,000
Total consideration					5,225,000	14,790,000	6,500,000
Immaterial correction	$ 188,145							$ 266,000

Derivative Liabilities (Details) (USD $)	1 Months Ended	3 Months Ended								12 Months Ended				12 Months Ended							12 Months Ended		3 Months Ended
Derivative Liabilities (Details) (USD $)	Aug. 31, 2012	Jan. 31, 2015	Oct. 31, 2014	Jul. 31, 2014	Apr. 30, 2014	Jan. 31, 2014	Oct. 31, 2013	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013	Aug. 16, 2012	Jan. 31, 2014 Additional paid in capital	Jan. 31, 2014 Series A Preferred Stock	Jan. 31, 2015 Estimate of Fair Value	Jan. 31, 2014 Estimate of Fair Value	Jan. 31, 2015 Common Stock Warrant	Jan. 31, 2015 Common Stock Warrant Estimate of Fair Value	Jan. 31, 2014 Common Stock Warrant Estimate of Fair Value	Jan. 31, 2014 Immaterial Valuation of Common Stock Warrants Adjustment	Jan. 31, 2013 Immaterial Valuation of Common Stock Warrants Adjustment	Jan. 31, 2013 Placement Agent Common Stock Warrant	Oct. 19, 2012 Placement Agent Common Stock Warrant	Oct. 31, 2012 Placement Agent Common Stock Warrant Estimate of Fair Value
Derivative Liabilities [Line Items]
Warrants exercisable (in shares)													1,200,000					1,400,000						200,000
Exercise price (USD per share)													$ 3.99					$ 4.00						$ 4.06
Net of transaction costs, allocated to the warrants	$ 1,425,000
Warrant liability at fair value																			1,834,000	4,117,000					4,139,000
Warrants liability		1,834,380				4,117,725				1,834,380	4,117,725					1,834,000	4,117,000
Valuation adjustment for warrants liability										2,283,345	140,928	489,434
Fair Value Adjustment of Warrants											609,000			412,000
Valuation adjustment															(196,952)
Annual volatility										55.00%
Risk-free rate										0.80%
Dividend yield										0.00%
Expected life										3 years
Annual volatility										58.24%													75.00%
Risk-free rate										1.07%													0.90%
Dividend yield										$ 0.000
Expected life										4 years													5 years
Earnings (loss) before income taxes										(12,898,466)	(11,817,648)	(8,267,266)									19,000
Deferred finance costs		387,199				44,898				387,199	44,898		611,000									51,000
Deemed dividends		286,000	269,000	253,000	230,000	449,000	374,000	16,000	342,000	1,038,310	1,180,904	176,048										150,000
Series A Preferred Stock		$ 6,637,978				$ 5,599,668				$ 6,637,978	$ 5,599,668										$ 609,000

Operating Leases (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2015	$ 1,040
2016	971
2017	1,007
2018	1,039
2019	967
Thereafter	1,468
Total	6,492
Rent expense	1,652	1,333	965
Facilities
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2015	1,035
2016	969
2017	1,007
2018	1,039
2019	967
Thereafter	1,468
Total	6,485
Equipment
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2015	5
2016	2
2017	0
2018	0
2019	0
Thereafter	0
Total	$ 7

Debt - Term Loan and Line of Credit Narrative (Details) (USD $)	12 Months Ended								0 Months Ended			1 Months Ended		0 Months Ended	12 Months Ended	0 Months Ended	12 Months Ended				0 Months Ended				12 Months Ended				0 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013	Aug. 30, 2012	Aug. 16, 2012	Jan. 31, 2015 Subordinated Debt	Jan. 31, 2013 Subordinated Debt	Aug. 16, 2012 Subordinated Debt	Dec. 13, 2013 Senior Notes	Jan. 31, 2015 Senior Notes	Jan. 31, 2014 Senior Notes	Aug. 31, 2012 Term loan	Aug. 16, 2012 Term loan	Dec. 13, 2013 Revolving Credit Facility	Jan. 31, 2015 Revolving Credit Facility	Nov. 21, 2014 Credit Agreement	Jan. 31, 2015 Credit Agreement	Feb. 03, 2014 Credit Agreement	Nov. 21, 2014 Credit Agreement Senior term loan	Nov. 21, 2014 Credit Agreement Revolving Credit Facility	Nov. 21, 2014 Minimum LIBOR Credit Agreement	Nov. 21, 2014 Minimum Base Rate Credit Agreement	Nov. 21, 2014 Maximum LIBOR Credit Agreement	Nov. 21, 2014 Maximum Base Rate Credit Agreement	Jan. 31, 2015 April 15, 2015 Credit Agreement	Jan. 31, 2015 April 16, 2015 through and including July 30, 2015 Credit Agreement	Jan. 31, 2015 July 31, 2015 through and including January 30, 2016 Credit Agreement	Jan. 31, 2015 January 31, 2016 through and including the maturity date Credit Agreement	Apr. 15, 2015 Subsequent Event Minimum LIBOR Credit Agreement	Apr. 15, 2015 Subsequent Event Minimum Base Rate Credit Agreement	Apr. 15, 2015 Subsequent Event Maximum LIBOR Credit Agreement	Apr. 15, 2015 Subsequent Event Maximum Base Rate Credit Agreement
Debt Instrument [Line Items]
Revolving line of credit					$ 5,000,000			$ 9,000,000											$ 10,000,000	$ 5,000,000
Subordinated term loan													4,120,000
Success fee included in the previous subordinated term loan												700,000
Success fees accruals				233,000
Commitment fee in connection with the term loan												75,000			5,000
Internal rate of return required by lender							17.00%
Payment of success fee	0	1,124,279	467,906
Convertible Note									8,500,000
Installment payments due									101,000
Borrowing under the revolving loan bears interest at a rate equal to LIBOR plus									5.25%					3.50%							4.25%	3.25%	5.25%	4.25%					4.25%	3.25%	6.25%	5.25%
Accrues interest rate						6.42%
Closing fee										116,000
Commitment fee percentage														0.40%
Repayments of Long-term Debt																7,400,000
Debt discount											112,000							315,000
Amortization of financing costs																401,000
Minimum liquidity																									5,000,000	6,500,000	7,000,000	7,500,000
Minimum EBITDA level																	$ 0								$ (2,500,000)	$ (1,750,000)	$ (750,000)	$ 500,000

Debt - Note Payable Narrative (Details) (USD $)	12 Months Ended				0 Months Ended
Debt - Note Payable Narrative (Details) (USD $)	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2015 Subordinated Debt	Nov. 20, 2013 Subordinated Debt Unsecured Subordinated Notes Due November, 2016
Debt Instrument [Line Items]
Debt term					3 years
Convertible Note					$ 900,000
Accrues interest rate				6.42%	8.00%
Principal Payments					300,000
Repayments of debt	$ 8,297,620	$ 10,348,214	$ 312,500		$ 600,000

Debt - Summary of Term Loan and Line of Credit (Details) (USD $)
In Thousands, unless otherwise specified

Jan. 31, 2015

Jan. 31, 2014

Debt Instrument [Line Items]

Total Debt and Capital Lease Obligations

$ 11,365

$ 9,425

Less: Current portion

1,282

1,620

Non-current portion of long-term debt

10,083

7,805

Senior Notes

Debt Instrument [Line Items]

Long-term Debt, Gross

10,000

8,298

^[1]

Debt discount

112

Subordinated Debt

Debt Instrument [Line Items]

Long-term Debt, Gross

900

Capital Lease Obligations

Debt Instrument [Line Items]

Capital Lease Obligations

$ 1,365

$ 227

[1]	January 31, 2014 balance represents total principal due, therefore it is not reduced by the debt discount of $112,000. In the consolidated balance sheets, the term loan is presented net of this discount.

Debt - Schedule of Future Principal Repayments of Long-Term Debt (Details) (USD $)
In Thousands, unless otherwise specified

Jan. 31, 2015

Debt Instrument [Line Items]

Capital Leases, Payments Due by 2015

$ 858

Total Payments Due by 2015

1,358

Capital Leases, Payments Due by 2016

457

Total Payments Due by 2016

1,207

Capital Leases, Payments Due by 2017

Total Payments Due by 2017

1,093

Total Payments Due by 2018

1,000

Total Payments Due by 2019

6,750

Capital Lease

1,408

^[1]

Total

11,408

Senior Notes

Debt Instrument [Line Items]

Debt Payments Due by 2015

500

Debt Payments Due by 2016

750

Debt Payments Due by 2017

1,000

Payments Due by 2018

1,000

Payments Due by 2019

6,750

Long-term Debt

$ 10,000

[1]	Future minimum lease payments include principal plus interest.

Debt - Contingent Earn-Out Provision Narrative (Details) (USD $)	12 Months Ended				0 Months Ended	1 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013	Jul. 30, 2013	Jan. 02, 2014 Interpoint Partners, LLC	Nov. 30, 2013 Interpoint Partners, LLC	Nov. 30, 2013 Interpoint Partners, LLC Note Payable
Debt Instrument [Line Items]
Asset purchase agreement				$ 3,500,000
Earn out paid in cash					1,300,000	1,300,000
Issuance of common shares					400,000	400,000
Face amount of debt issued for earnout consideration	900,000						900,000
Total purchase price					2,700,000
Valuation adjustment for contingent earn-out	$ 0	$ 3,580,441	$ 86,839

Debt - Convertible Subordinated Notes Payable, Private Placement Investment Narrative (Details) (USD $)	12 Months Ended						1 Months Ended			12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013	Aug. 16, 2012 Private Placement	Nov. 02, 2012 Private Placement Convertible Subordinated Notes Payable	Aug. 16, 2012 Private Placement Convertible Subordinated Notes Payable	Aug. 31, 2012 Great Point Partners And Noro Moseley Partners	Aug. 16, 2012 Great Point Partners And Noro Moseley Partners	Aug. 16, 2012 Great Point Partners And Noro Moseley Partners Subordinated Debt	Jan. 31, 2012 Series A Preferred Stock Convertible Notes to Preferred Stock	Nov. 02, 2012 Series A Preferred Stock Convertible Notes to Preferred Stock
Debt Instrument [Line Items]
Private placement investment				$ 12,000,000
Convertible notes payable					5,699,577	5,699,577			5,699,577
Subordinated notes convert into preferred stock								1,583,220
Debt discount								1,934,000
Amortization of debt discount	47,552	4,327	111,583				112,000
New issuance of series A convertible preferred stock											1,583,210
Loss upon conversion	$ 0	$ 0	$ 5,970,002							$ 5,913,000

Debt - Interest Rate Swap Narrative (Details) (Interest Rate Swap, USD $)	Jan. 31, 2015
Interest Rate Swap
Derivative [Line Items]
Fixed interest rate	6.42%
Notional amount	$ 8,500,000
Derivative liability	$ 111,000

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

+ References+ Details

Goodwill and Intangible Assets - Schedule of Goodwill Activity (Details) (USD $)	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Goodwill [Roll Forward]
Goodwill, Beginning of Period	$ 11,933,683	$ 12,133,000
Goodwill acquired during the year	4,251,000	108,000
Adjustments to goodwill during the year		(307,000)
Goodwill, End of Period	$ 16,184,667	$ 11,933,683

Goodwill and Intangible Assets - Schedule of Goodwill and Intangibles (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Intangible Assets, Net (Including Goodwill) [Abstract]
Accumulated Amortization	$ 3,327	$ 1,930
Net Assets	9,500
Gross Assets (Including Goodwill)	12,827	14,106
Net Assets (Including Goodwill)	9,500	12,176
Error in Original Valuation \| Restatement Adjustment \| Meta
Intangible Assets, Net (Including Goodwill) [Abstract]
Indefinite-lived assets		364
Maximum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	15 years
Minimum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	1 year
Trade name
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	1 year
Gross Assets	26
Accumulated Amortization	26
Net Assets	0
Client relationships
Intangible Assets, Net (Including Goodwill) [Abstract]
Gross Assets	5,932	5,285
Accumulated Amortization	1,548	862
Net Assets	4,384	4,423
Client relationships \| Maximum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	15 years	15 years
Client relationships \| Minimum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	10 years	10 years
Covenants not to compete
Intangible Assets, Net (Including Goodwill) [Abstract]
Gross Assets	856	856
Accumulated Amortization	606	533
Net Assets	250	323
Covenants not to compete \| Maximum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	15 years	15 years
Covenants not to compete \| Minimum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	6 months	6 months
Supplier agreements
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	5 years
Gross Assets	1,582	1,582
Accumulated Amortization	778	461
Net Assets	804	1,121
License agreement
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	15 years
Gross Assets	4,431	4,431
Accumulated Amortization	369	74
Net Assets	4,062	4,357
Trade name
Intangible Assets, Net (Including Goodwill) [Abstract]
Indefinite-lived assets	$ 1,952	$ 1,952

Goodwill and Intangible Assets - Schedule of Future Amortization Expense (Details) (USD $) In Thousands, unless otherwise specified	Jan. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
2015	$ 1,345
2016	1,298
2017	1,088
2018	863
2019	826
Thereafter	4,080
Net Assets	$ 9,500

Income Taxes - Components of Income Tax Expense (Details) (USD $)	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Current tax benefit (expense):
Federal	$ 131,816	$ (8,705)	$ (9,391)
State	34,611	130,048	(37,594)
Total current tax expense	166,427	121,343	(46,985)
Deferred tax benefit (expense):
Federal	663,681	26,491	2,642,580
State	56,901	(47,376)	292,942
Total deferred tax beneit (expense)	720,582	(20,885)	2,935,522
Current and deferred income tax benefit	$ 887,009	$ 100,458	$ 2,888,537

- Definition

Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References+ Details

- Definition

Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.

+ References+ Details

- Definition

Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References+ Details

- Definition

Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References+ Details

- Definition

Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References+ Details

- Definition

Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References+ Details

Income Taxes - Tax Provision at Statutory Rate Reconciliation (Details) (USD $)	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]
Federal tax benefit at statutory rate	$ 4,385,479	$ 4,018,000	$ 2,810,870
State and local taxes, net of federal benefit	325,966	488,626	255,348
Change in valuation allowance	(4,030,864)	(3,659,160)	2,000,295
Loss from conversion of notes payable	0	0	(1,937,411)
Incentive stock options	(421,366)	(343,117)	0
Transaction costs	(5,291)	(78,476)	(339,320)
Change in fair value of warrants liability	776,337	(159,249)	166,408
Other	(44,719)	(351,857)	(45,540)
Reserve for uncertain tax position	164,127	(11,642)	0
Other	(262,660)	197,333	(22,113)
Current and deferred income tax benefit	$ 887,009	$ 100,458	$ 2,888,537

Income Taxes - Schedule of Deferred Tax Assets and Tax Carryforwards (Details) (USD $)	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Deferred tax assets:
Allowance for doubtful accounts	$ 245,252	$ 98,661
Deferred revenue	372,275	19,561
Accruals	174,658	351,827
Net operating loss carryforwards	14,905,174	7,763,718
Stock compensation expense	438,659	362,145
Property and equipment	0	147,691
AMT credit	102,144	102,144
Other	8,912	62,783
Total deferred tax assets	16,247,074	8,908,530
Valuation Allowance	(12,554,242)	(7,666,626)	(7,834,990)
Net deferred tax assets	3,692,832	1,241,904
Deferred tax liabilities:
Property and Equipment	(21,755)	0
Definite-lived intangible assets	(3,671,077)	(1,241,904)
Indefinite-lived intangibles	(9,575)	(720,581)
Total deferred tax liabilities	(3,702,407)	(1,962,485)
Net deferred tax liabilities	$ (9,575)	$ (720,581)

Income Taxes - Additional Information (Details) (USD $)	12 Months Ended
Income Taxes - Additional Information (Details) (USD $)	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Income Tax Contingency [Line Items]
Valuation allowance	$ 12,554,242	$ 7,666,626	$ 7,834,990
Change in valuation allowance	(4,030,864)	(3,659,160)	2,000,295
Unrecognized operating loss carryforwards for stock options	1,592,000
Unrecognized deferred tax asset for operating loss carryforwards for stock options	588,000
Liability for uncertain tax positions	0	181,000
Interest and penalties	0	60,000
Internal Revenue Service (IRS)
Income Tax Contingency [Line Items]
Operating loss carryforwards	40,944,000
Change in valuation allowance	4,887,000
Internal Revenue Service (IRS) \| Alternative Minimum Tax
Income Tax Contingency [Line Items]
Operating loss carryforwards	40,944,000
State
Income Tax Contingency [Line Items]
Operating loss carryforwards, subject to expire next twenty fiscal years	$ 20,710,000

Income Taxes - Unrecognized Tax Benefits (Details) (USD $)	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Unrecognized tax benefits, beginning of period	$ 121,000	$ 122,000	$ 0
Additions for tax positions of prior years	0	0	122,000
Reductions for tax positions of prior years	0	(1,000)	0
Reductions attributable to lapse of statute of limitations	(121,000)	0	0
Unrecognized tax benefits, end of period	$ 0	$ 121,000	$ 122,000

Major Clients (Details) (Customer Concentration Risk)	12 Months Ended
Major Clients (Details) (Customer Concentration Risk)	Jan. 31, 2015 customers	Jan. 31, 2014 customers	Jan. 31, 2013 customers
Revenue
Concentration Risk
Concentration risk, number of customers	0	1	2
Concentration risk, percentage		11.00%
Revenue \| Customer A
Concentration Risk
Concentration risk, percentage			7.00%
Revenue \| Customer B
Concentration Risk
Concentration risk, percentage			5.00%
Accounts Receivable
Concentration Risk
Concentration risk, number of customers	2	2	2
Accounts Receivable \| Customer A
Concentration Risk
Concentration risk, percentage	16.00%	13.00%	16.00%
Accounts Receivable \| Customer B
Concentration Risk
Concentration risk, percentage	10.00%	9.00%	11.00%

Employee Retirement Plan (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Employee Retirement Plan [Abstract]
Matching contribution percent	100.00%
Maximum contribution as a percent of participant compensation	4.00%
Defined contribution plan, cost recognized	$ 440	$ 370	$ 289

Employee Stock Purchase Plan (Details) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award
Shares remaining available for grant	97,285
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares authorized to be purchased under Employee Stock Purchase Plan	1,000,000
Employee Stock Purchase Plan, maximum annual contribution per employee, percent	10.00%
Employee Stock Purchase Plan, percent of fair market value, prior year	85.00%
Employee Stock Purchase Plan, percent of fair market value, current year	85.00%
Allocated share-based compensation expense	$ 14	$ 42	$ 32
Cash received from purchase of shares under Employee Stock Purchase Plan	$ 82	$ 169	$ 76
Purchase price discount	85.00%
Closing price on January 2, 2015	$ 4.05
Employee Stock Purchase Plan \| $4.08 per share
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchased during period, shares, Employee Stock Purchase Plan	11,141
Stock purchased during period, price per share, Employee Stock Purchase Plan	$ 4.08
Employee Stock Purchase Plan \| $3.68 per share
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchased during period, shares, Employee Stock Purchase Plan	9,900
Stock purchased during period, price per share, Employee Stock Purchase Plan	$ 3.68
Employee Stock Purchase Plan \| $3.17 per share
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchased during period, shares, Employee Stock Purchase Plan	36,858
Stock purchased during period, price per share, Employee Stock Purchase Plan	$ 3.17
Employee Stock Purchase Plan \| $5.67 per share
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchased during period, shares, Employee Stock Purchase Plan	9,115
Stock purchased during period, price per share, Employee Stock Purchase Plan	$ 5.67

Stock Based Compensation - Additional Information (Details) (USD $)	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding	2,437,323
Options exercisable	1,192,220
Compensation cost not yet recognized	$ 2,479,000
Weighted average period of recognition for compensation cost	2 years 0 months 0 days
Proceeds from exercise of stock options and stock purchase plan	551,583	1,356,060	282,628
Change in control percentage	0.2
$1.65 to $8.17
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding	463,924
Exercise price range, lower range limit	$ 1.65
Exercise price range, upper range limit	$ 8.17
Options exercisable	454,424
$1.65 to $2.00
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding	519,978
Exercise price range, lower range limit	$ 1.65
Exercise price range, upper range limit	$ 2.00
Options exercisable	280,667
$2.08 to $4.00
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding	1,453,421
Exercise price range, lower range limit	$ 2.08
Exercise price range, upper range limit	$ 4.00
Options exercisable	457,129
$4.08 to $8.17
Share-based Compensation Arrangement by Share-based Payment Award
Exercise price range, lower range limit	$ 4.08
Exercise price range, upper range limit	$ 8.17
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding	2,437,323	2,304,407	2,685,237
Options issued	1,318,078
Options expired	168,060
Options forfeited	770,947
Options exercised	246,155
Options exercisable	1,192,220
Allocated share-based compensation expense	1,655,000	1,507,000	664,000
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award
Compensation cost not yet recognized	372,000
Allocated share-based compensation expense	$ 265,000	$ 112,000	$ 260,000
2005 and 2013 Incentive Compensation Plans \| Blended Equity Awards (Stock Options, Stock Appreciation Rights, Resticted Stock)
Share-based Compensation Arrangement by Share-based Payment Award
Equity awards authorized	4,500,000
Term of options granted	10 years
Vesting period	3 years
Options outstanding	1,737,323	1,473,425
Executive Inducement Grants \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding	700,000	830,982
Options issued	300,000	0	675,000
Options expired	125,694		177,783
Options forfeited	99,722	186,790
Options exercised	205,566	105,556	88,889
2013 Incentive Compensation Plan \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period	1 year

Stock Based Compensation - Summary of Stock Option Activity (Details) (USD $)	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Stock Option Activity
Options, Outstanding - end of year	2,437,323
Options, Exercisable — end of year	1,192,220
Weighted Average Exercise Price Activity
Weighted Average Exercise Price, Outstanding - end of year (USD per share)	$ 4.52
Weighted Average Exercise Price, Exercisable - end of year (USD per share)	$ 3.83
Stock Options
Stock Option Activity
Options, Outstanding - beginning of year	2,304,407	2,685,237
Granted options	1,318,078
Options, Exercised	(246,155)
Options, Expired	(168,060)
Options, Forfeited	(770,947)
Options, Outstanding - end of year	2,437,323	2,304,407	2,685,237
Options, Exercisable — end of year	1,192,220
Aggregate intrinsic value of outstanding options at year end	$ 9,798,038
Aggregate intrinsic value of exercisable options at year end	4,792,724
Weighted Average Exercise Price Activity
Weighted Average Exercise Price, Outstanding - beginning of year (USD per share)	$ 4.46
Weighted Average Exercise Price, Granted (USD per share)	$ 4.95
Weighted Average Exercise Price, Exercised (USD per share)	$ 1.91
Weighted Average Exercise Price, Expired (USD per share)	$ 5.31
Weighted Average Exercise Price, Forfeited (USD per share)	$ 5.75
Weighted Average Exercise Price, Outstanding - end of year (USD per share)	$ 4.52	$ 4.46
Weighted average grant date fair value of options granted during year	$ 2.90	$ 4.42	$ 2.02
Weighted Average Exercise Price, Exercisable - end of year (USD per share)	$ 3.83
Total intrinsic value of options exercised during the year	$ 990,000	$ 2,673,000	$ 570,000

Stock Based Compensation - Weighted Average Assumptions (Details) (USD $)	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Share-based Compensation [Abstract]
Expected life	6 years	6 years	5 years
Risk-free interest rate	1.35%	1.81%	0.35%
Weighted average volatility factor	60.00%	66.00%	57.00%
Dividend yield	$ 0	$ 0	$ 0
Forfeiture rate	22.00%	21.00%	0.00%
Number of Options Outstanding	2,437,323
Number of Options Exercisable	1,192,220
Average Exercise Price, Outstanding (USD per share)	$ 4.52
Average Exercise Price, Exercisable (USD per share)	$ 3.83
Remaining Life in Years, Outstanding	7 years 10 months 28 days
Remaining Life in Years, Exercisable	6 years 8 months 1 day

Stock Based Compensation - Schedule of Restricted Stock Award Activity (Details) (Restricted Stock, USD $)	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Restricted Stock
Restricted Stock Award Activity
Non-vested number of shares, beginning of period	29,698	137,325	126,457
Shares granted	120,306	29,698	137,325
Shares vested	(29,698)	(137,325)	(126,457)
Shares forfeited/expired	0	0	0
Non-vested number of shares, end of period	120,306	29,698	137,325
Weighted Average Fair Value Activity
Weighted average grant date fair vale, at beginning of period (USD per share)	$ 6.01	$ 2.01	$ 1.68
Weighted average grant date fair value, granted (USD per share)	$ 4.31	$ 6.65	$ 2.01
Weighted average grant date fair value, vested (USD per share)	$ 6.65	$ 2.01	$ 1.79
Weighted average grant date fair value, forfeited/expired (USD per share)	$ 0.00	$ 0.00	$ 0.00
Weighted average grant date fair vale, at end of period (USD per share)	$ 4.31	$ 6.01	$ 2.01

Quarterly Results of Operations (Unaudited) - Selected Financial Information (Details) (USD $)	3 Months Ended								12 Months Ended
	Jan. 31, 2015	Oct. 31, 2014	Jul. 31, 2014	Apr. 30, 2014	Jan. 31, 2014	Oct. 31, 2013	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Effect of Fourth Quarter Events [Line Items]
Revenues	$ 6,595,000	$ 6,837,000	$ 7,242,000	$ 6,951,000	$ 6,517,000	$ 6,732,000	$ 8,773,000	$ 6,473,000	$ 27,625,407	$ 28,494,703	$ 23,766,803
Gross profit	3,209,000	3,793,000	4,221,000	3,398,000	2,887,000	3,597,000	5,536,000	3,297,000	14,621,000	15,317,000
Operating profit (loss)	(4,948,000)	(2,713,000)	(2,059,000)	(3,593,000)	(4,802,000)	(1,140,000)	997,000	(1,373,000)	(13,312,097)	(6,318,031)	(834,931)
Net loss	(4,810,000)	(2,256,000)	(2,275,000)	(2,671,000)	(1,947,000)	(6,232,000)	(828,000)	(2,710,000)	(12,011,457)	(11,717,190)	(5,378,729)
Less: deemed dividends on Series A Preferred Shares	(286,000)	(269,000)	(253,000)	(230,000)	(449,000)	(374,000)	(16,000)	(342,000)	(1,038,310)	(1,180,904)	(176,048)
Net earnings (loss) attributable to common shareholders	(5,096,000)	(2,525,000)	(2,528,000)	(2,901,000)	(2,396,000)	(6,607,000)	(844,000)	(3,051,000)	(13,049,767)	(12,898,094)	(5,554,777)
Basic net loss per share (in dollars per share)	$ (0.28)	$ (0.14)	$ (0.14)	$ (0.16)	$ (0.14)	$ (0.50)	$ (0.07)	$ (0.24)	$ (0.71)	$ (0.94)	$ (0.48)
Diluted net loss per share (in dollars per share)	$ (0.28)	$ (0.14)	$ (0.14)	$ (0.16)	$ (0.14)	$ (0.50)	$ (0.07)	$ (0.24)	$ (0.71)	$ (0.94)	$ (0.48)
Basic and diluted weighted average shares outstanding (shares)	18,417,000	18,301,000	18,174,000	18,146,000	16,337,000	13,258,000	12,862,000	12,534,000	18,261,800	13,747,700	11,634,540
Settlement of earn out consideration						4,101,000
Immaterial correction						188,145
Trade name
Effect of Fourth Quarter Events [Line Items]
Indefinite-lived assets	$ 1,952,000				$ 1,952,000				$ 1,952,000	$ 1,952,000

Private Placement Investment - Additional Information (Details) (USD $)

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Aug. 31, 2012

Jan. 31, 2014

Jan. 31, 2013

Jan. 31, 2015

Aug. 16, 2012

Jan. 31, 2015

Common Stock Warrant

Aug. 16, 2012

Private Placement

Jan. 31, 2015

Private Placement

Aug. 16, 2012

Private Placement

Series A Preferred Stock

Jan. 31, 2014

Private Placement

Series A Preferred Stock

Aug. 16, 2012

Private Placement

Common Stock Warrant

Aug. 16, 2012

Private Placement

Convertible Subordinated Notes Payable

Nov. 02, 2012

Private Placement

Convertible Subordinated Notes Payable

Class of Stock [Line Items]

Proceeds allocation

$ 12,000,000

$ 6,546,146

^[1]

$ 1,688,116

^[2]

$ 3,765,738

^[3]

Issuance of common stock

2,416,785

Preferred stock dividend rate

0.00%

Share price (USD per share)

$ 3.00

$ 8.00

Warrants exercisable (in shares)

1,200,000

1,400,000

1,200,000

Exercise price (USD per share)

$ 3.99

$ 4.00

$ 3.99

Convertible notes payable

5,699,577

Common shares issued for convertible note and accrued interest (in shares)

1,583,210

Placement and other advisor fees

1,894,000

Cost of warrants issued

754,000

Deferred finance costs

44,898

387,199

611,000

Preferred stock, discount on shares

1,020,000

4,410,000

Issuance of common stock warrants

$ 263,000

$ 22,425,000

$ 2,441,852

[1]	The Series A Preferred Stock convert on a 1:1 basis into common stock, but differ in value from common stock due to the downside protection relative to common stock in the event the Company liquidates, and the downside protection, if, after four years, the holder has not converted and the stock is below $3.00. The fair value of Series A Preferred Stock was determined using a Monte-Carlo simulation following a Geometric Brownian Motion, using the following assumptions: annual volatility of 75%, risk-free rate of 0.9% and dividend yield of 0.0%. The model also utilized the following assumptions to account for the conditions within the agreement: after four years, if the simulated common stock price fell below a price of $3.00 per share, the convertible preferred stock would automatically convert to common stock on a 1:1 basis moving forward at a price of exactly $3.00 per share and a forced conversion if the simulated stock price exceeded $8.00 per share.
[2]	The fair value of the common stock warrants was determined using a Monte-Carlo simulation following a Geometric Brownian motion, using the following assumptions: annual volatility of 75%, risk-free rate of 0.9%, dividend yield of 0.0% and expected life of 5 years. Because the dilutive down-round financing was subject to approval by shareholder vote which had not happened at the time of the valuation, the model utilized the assumption that the down-round financing would not occur within the simulation.
[3]	The fair value of convertible subordinated notes payable was determined based on its current yield as compared to that of those currently outstanding in the marketplace. Management reviewed the convertible note agreement and determined that the note's interest rate is a reasonable representative of a market rate; therefore the face or principal amount of the loan is a reasonable estimate of its fair value.

Private Placement Investment - Schedule of Investment Allocation (Details) (USD $)

0 Months Ended

12 Months Ended

Aug. 16, 2012

Jan. 31, 2015

Instruments:

Annual volatility

58.24%

Risk-free rate

1.07%

Expected life

4 years

Private Placement

Instruments:

Total investment, Fair Value

$ 18,463,397

Proceeds allocation

12,000,000

Private Placement | Common Stock Warrant

Instruments:

Warrants, Fair Value

2,856,000

Proceeds allocation

1,688,116

^[1]

75.00%

0.90%

0.00%

5 years

Private Placement | Convertible Subordinated Notes Payable

Instruments:

Convertible subordinated notes payable, Fair Value

5,699,577

Proceeds allocation

3,765,738

^[2]

Private Placement | Series A Preferred Stock

Instruments:

Series A Preferred Stock, Fair Value

9,907,820

Proceeds allocation

$ 6,546,146

^[3]

Maximum conversion period

4 years

Stock price at time of conversion (USD per share)

$ 3.00

75.00%

0.90%

0.00%

Private Placement | Minimum | Series A Preferred Stock

Instruments:

Stock price at time of conversion (USD per share)

$ 3.00

Private Placement | Maximum | Series A Preferred Stock

Instruments:

Stock price at time of conversion (USD per share)

$ 8.00

[1]	The fair value of the common stock warrants was determined using a Monte-Carlo simulation following a Geometric Brownian motion, using the following assumptions: annual volatility of 75%, risk-free rate of 0.9%, dividend yield of 0.0% and expected life of 5 years. Because the dilutive down-round financing was subject to approval by shareholder vote which had not happened at the time of the valuation, the model utilized the assumption that the down-round financing would not occur within the simulation.
[2]	The fair value of convertible subordinated notes payable was determined based on its current yield as compared to that of those currently outstanding in the marketplace. Management reviewed the convertible note agreement and determined that the note's interest rate is a reasonable representative of a market rate; therefore the face or principal amount of the loan is a reasonable estimate of its fair value.
[3]	The Series A Preferred Stock convert on a 1:1 basis into common stock, but differ in value from common stock due to the downside protection relative to common stock in the event the Company liquidates, and the downside protection, if, after four years, the holder has not converted and the stock is below $3.00. The fair value of Series A Preferred Stock was determined using a Monte-Carlo simulation following a Geometric Brownian Motion, using the following assumptions: annual volatility of 75%, risk-free rate of 0.9% and dividend yield of 0.0%. The model also utilized the following assumptions to account for the conditions within the agreement: after four years, if the simulated common stock price fell below a price of $3.00 per share, the convertible preferred stock would automatically convert to common stock on a 1:1 basis moving forward at a price of exactly $3.00 per share and a forced conversion if the simulated stock price exceeded $8.00 per share.

Private Placement Investment - Series A Convertible Preferred Stock Narrative (Details) (USD $)	12 Months Ended				12 Months Ended				12 Months Ended		0 Months Ended	12 Months Ended	0 Months Ended	12 Months Ended						12 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013	Aug. 16, 2012 Common stock	Jan. 31, 2015 Series A Preferred Stock	Jan. 31, 2014 Series A Preferred Stock	Jan. 31, 2013 Series A Preferred Stock	Jan. 31, 2012 Series A Preferred Stock	Jan. 31, 2015 Convertible Notes to Preferred Stock Series A Preferred Stock	Nov. 02, 2012 Convertible Notes to Preferred Stock Series A Preferred Stock	Aug. 16, 2012 Private Placement	Jan. 31, 2015 Private Placement	Aug. 16, 2012 Private Placement Series A Preferred Stock	Jan. 31, 2015 Private Placement Series A Preferred Stock	Jan. 31, 2014 Private Placement Series A Preferred Stock	Jan. 31, 2013 Private Placement Series A Preferred Stock	Nov. 02, 2012 Private Placement Convertible Subordinated Notes Payable	Aug. 16, 2012 Private Placement Convertible Subordinated Notes Payable	Nov. 02, 2012 Private Placement Convertible Notes to Preferred Stock Series A Preferred Stock	Jan. 31, 2015 Minimum Convertible Notes to Preferred Stock Series A Preferred Stock	Aug. 16, 2012 Minimum Private Placement Series A Preferred Stock	Jan. 31, 2015 Maximum Convertible Notes to Preferred Stock Series A Preferred Stock	Aug. 16, 2012 Maximum Private Placement Series A Preferred Stock
Class of Stock [Line Items]
New issuance of series A convertible preferred stock													2,416,785
Preferred stock, par value (USD per share)										$ 5.80			$ 3.00
Market Price, date of agreement				$ 3.82
Period over which share price is evaluated	10 days
Share price (USD per share)													$ 3.00		$ 8.00
Period over which trade volume is evaluated														60 days
Average daily trading volume for period (in shares)														100,000
Stock price at time of conversion (USD per share)														$ 3.00						$ 3.00	$ 3.00	$ 8.00	$ 8.00
Preferred stock, discount on shares													$ 1,020,000		$ 4,410,000
Beneficial conversion feature																2,686,000
Accretion of Preferred Stock discount	(47,552)	(4,327)	(111,583)		1,038,310		176,048							1,038,000	1,180,904	176,000
Convertible notes payable																	5,699,577	5,699,577
Common shares issued for convertible note and accrued interest (in shares)											1,583,210	1,583,210
Loss upon conversion	0	0	5,970,002						5,913,000
Issuance of shares at redemption value for conversion of notes payable										9,183,000
Carrying value and unamortized deferred financing costs										3,270,000
Aggregate redemption value																			4,750,000
Difference between fair value and redemption value recorded as additional paid in capital										4,433,000
Annual volatility	58.24%								75.00%				75.00%
Risk-free rate	1.07%								0.80%				0.90%
Dividend yield									0.00%				0.00%
Convertible redeemable preferred stock, shares outstanding					2,949,995	2,949,995	3,999,995	0
Redemption price per share (USD per share)		$ 3.00
Shares converted	1,050,000					1,050,000
Amount converted	$ 0	$ (3,150,000)	$ 0			$ (3,150,000)
Conversion basis									1				1

Private Placement Investment - Schedule of Series A Preferred Stock Activity (Details) (USD $)

12 Months Ended

Jan. 31, 2015

Jan. 31, 2014

Jan. 31, 2013

Increase (Decrease) in Shares of Temporaty Equity [Roll Forward]

Conversion of Preferred Stock to Common Stock

(1,050,000)

Increase (Decrease) in Temporary Equity [Roll Forward]

Conversion of Preferred Stock to Common Stock

$ 0

$ (3,150,000)

$ 0

Accretion of Preferred Stock discount

(47,552)

(4,327)

(111,583)

Series A Preferred Stock

Increase (Decrease) in Shares of Temporaty Equity [Roll Forward]

Beginning Balance (in shares)

2,949,995

3,999,995

Issuance from private placement, at redemption value (in shares)

2,416,785

Issuance of shares at redemption value for conversion of notes payable (in shares)

1,583,210

Conversion of Preferred Stock to Common Stock

(1,050,000)

Period End Balance (in shares)

2,949,995

3,999,995

Increase (Decrease) in Temporary Equity [Roll Forward]

Beginning Balance

5,599,668

7,765,716

Issuance from private placement, at redemption value

7,250,355

Discount related to warrants

(704,209)

^[1]

(2,685,973)

Discount related to issuance cost

(1,020,135)

Issuance of shares at redemption value for conversion of notes payable

4,749,630

Conversion of Preferred Stock to Common Stock

(3,150,000)

Accretion of Preferred Stock discount

1,038,310

176,048

Valuation adjustment

(196,952)

Period End Balance

6,637,978

5,599,668

7,765,716

Private Placement | Series A Preferred Stock

Increase (Decrease) in Temporary Equity [Roll Forward]

Accretion of Preferred Stock discount

$ 1,038,000

$ 1,180,904

$ 176,000

[1]	The discount related to warrants represents the difference between the redemption value of the Series A Preferred Stock, issued in conjunction with the private placement, and its allocated proceeds.

Private Placement Investment - Common Stock Warrants Narrative (Details) (USD $)	1 Months Ended	12 Months Ended				0 Months Ended	12 Months Ended	3 Months Ended
	Aug. 31, 2012	Jan. 31, 2015	Jan. 31, 2014	Aug. 16, 2012	Jan. 31, 2015 Common Stock Warrant	Aug. 16, 2012 Private Placement Common Stock Warrant	Jan. 31, 2015 Private Placement Common Stock Warrant	Jan. 31, 2013 Placement Agent Common Stock Warrant	Oct. 19, 2012 Placement Agent Common Stock Warrant	Jan. 31, 2015 Estimate of Fair Value	Jan. 31, 2014 Estimate of Fair Value	Jan. 31, 2015 Estimate of Fair Value Common Stock Warrant	Jan. 31, 2014 Estimate of Fair Value Common Stock Warrant	Oct. 31, 2012 Estimate of Fair Value Placement Agent Common Stock Warrant
Class of Stock [Line Items]
Warrants exercisable (in shares)				1,200,000	1,400,000	1,200,000			200,000
Weighted average exercise price (USD per share)				$ 3.99	$ 4.00	$ 3.99			$ 4.06
Maximum Warrants exercisable period							5 years	5 years
Derivative liability												$ 1,834,000	$ 4,117,000	$ 4,139,000
Net of transaction costs, allocated to the warrants	1,425,000					1,425,000
Fair value of warrants						2,856,000			754,000
Annual volatility		58.24%				75.00%		75.00%
Risk-free rate		1.07%				0.90%		0.90%
Dividend yield						0.00%		0.00%
Expected life		4 years				5 years		5 years
Warrants liability		$ 1,834,380	$ 4,117,725							$ 1,834,000	$ 4,117,000

Private Placement Investment - Schedule of Warrants Issued and Outstanding (Details) (USD $)	Aug. 16, 2012	Jan. 31, 2015 Common Stock Warrant	Jan. 31, 2015 Placement Agent Common Stock Warrant	Jan. 31, 2015 Private Placement Common Stock Warrant
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares issuable (in shares)	1,200,000	1,400,000	200,000	1,200,000
Weighted average exercise price (USD per share)	$ 3.99	$ 4.00	$ 4.06	$ 3.99

Stockholders' Equity - Additional Information (Details) (Common stock, USD $) In Thousands, except Share data, unless otherwise specified	0 Months Ended
	Nov. 27, 2013
Common stock
Class of Stock [Line Items]
Stock issued during period, new issues (in shares)	3,450,000
Options exercised	450,000
Shares issued, price per share (USD per share)	$ 6.50
Proceeds from issuance of common stock, net	$ 20,493
Underwriting discounts and commissions	1,680
Offering expenses	$ 158

Valuation and Qualifying Accounts and Reserves (Details) (USD $)	12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2013
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 267,264
Charged to Costs and Expenses	2,283,345	140,928	489,434
Balance at End of Period	665,962	267,264
Allowance for doubtful accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	267,000	134,000	100,000
Charged to Costs and Expenses	441,000	331,000	67,000
Charged to Other Accounts	1,000	0	34,000
Deductions	(43,000)	(198,000)	(67,000)
Balance at End of Period	666,000	267,000	134,000
Valuation allowance on deferred tax assets
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	7,667,000	7,835,000	9,835,000
Charged to Costs and Expenses	4,031,000	(209,000)	(2,000,000)
Charged to Other Accounts	(41,000)	41,000	0
Deductions	897,000	0	0
Balance at End of Period	$ 12,554,000	$ 7,667,000	$ 7,835,000

Major Clients	12 Months Ended
Major Clients	Jan. 31, 2015
Major Clients [Abstract]
MAJOR CLIENTS	MAJOR CLIENTS During fiscal year 2014, no individual client accounted for 10% or more of our total revenues. Two clients represented 16% and 10%, respectively, of total accounts receivable as of January 31, 2015. During fiscal year 2013, one client, Montefiore Medical Center, accounted for 11% of total revenues. Two clients represented 13% and 9%, respectively, of total accounts receivable as of January 31, 2014. During fiscal year 2012, two clients accounted for 7% and 5%, respectively, of total revenues. Two clients represented 16% and 11%, respectively, of total accounts receivable as of January 31, 2013.